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ABSTRACT: Small-molecule-induced protein depletion technol-
ogies, also called inducible degrons, allow degradation of
genetically engineered target proteins within cells and animals.
Here, we design and develop the BromoTag, a new inducible
degron system comprising a Brd4 bromodomain L387A variant as
a degron tag that allows direct recruitment by heterobifunctional
bumped proteolysis targeting chimeras (PROTACs) to hijack the
VHL E3 ligase. We describe extensive optimization and structure−
activity relationships of our bump-and-hole−PROTACs using a
CRISPR knock-in cell line expressing model target BromoTag-
Brd2 at endogenous levels. Collectively, our cellular and
mechanistic data qualifies bumped PROTAC AGB1 as a potent,
fast, and selective degrader of BromoTagged proteins, with a
favorable pharmacokinetic profile in mice. The BromoTag adds to the arsenal of chemical genetic degradation tools allowing us to
manipulate protein levels to interrogate the biological function and therapeutic potential in cells and in vivo.
1. INTRODUCTION
Targeted protein degradation is rapidly established as a
powerful modality of chemical biology and drug discovery.
Proteolysis targeting chimeras (PROTACs) are heterobifunc-
tional molecules which hijack the ubiquitin proteasome system
by recruiting an E3 ubiquitin ligase to a target protein of
interest, promoting the protein’s polyubiquitination and
subsequent proteasomal degradation.1−4 The ability to rapidly
remove a protein entirely, as opposed to merely blocking a
single activity or an interaction, offers an attractive approach to
study the target protein biology, therapeutic potential, and
pharmacological properties. However, the PROTAC approach
is limited by the availability of small-molecule ligands that
engage the protein target. While good ligands are available for
many target proteins, a large proportion of the human
proteome lacks such binding ligands.5 It is therefore important
to develop new methodologies to address unligandable
proteins, many of which remain underexplored in biology
and disease.
To deal with proteins that lack binding ligands, a
complementary strategy involves modifying the gene which
encodes for the protein of interest by adding a tag, also called
the “degron tag”, which allows small molecules to bind to and
directly recruit the E3 ligase to ubiquitinate and promote
degradation of the target protein. Examples of tag-based
degron systems include the auxin-inducible degron (AID),
whereby a target protein is fused with the AID/IAA17 degron
sequence that is recognized by the plant cullin RING E3 ligase
TIR1 in the presence of the molecular glue auxin6 or in recent
developments of bumped analogues selectively targeting
mutant TIR1;7,8 HaloPROTACs, bifunctional molecules that
bear a chloroalkane warhead which forms a covalent bond with
a HaloTag-fused target protein at one end and a von Hippel−
Lindau (VHL) E3 ligase ligand at the other end;9,10 and
dTAGs, bifunctional molecules which bind to a FKBP12F36V
tag that is fused to the target protein at one end and either
cereblon (CRBN) or VHL ligases at the other end.11,12 These
approaches have been used successfully to induce targeted
protein degradation in cells and in vivo, but they all have
disadvantages and limitations. For example, AID methods can
be leaky (background target degradation even prior to auxin
dosage), require high concentrations of auxin to work, and also
require inconvenient additional engineering to allow for the
expression of the non-native plant E3 ligase; all limitations lead
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to possible off-target effects. HaloPROTACs react covalently
with the tagged protein and thus require stoichiometric
modification of the tagged protein to induce maximal
degradation, thereby lacking the substoichiometric, catalytic
mode of action, which is an advantage of non-covalent
degraders. As a result, HaloPROTACs tend not to achieve
complete target degradation and tend to plateau at Dmax ∼85−
90% even at high doses.9,10 CRBN-based dTAGs bear
phthalimide-based ligands which exhibit chemical instability
and off-target effects.13
There is a significant scope to expand the chemical and
biological space of degron-tag technologies, so we set out to
develop a novel system that offers a complementary approach,
alternative to the existing methods. In this work, we describe
the development of a novel degron tag called the “BromoTag”.
The new tag system leverages significant developments and
discoveries in the past decade from our laboratory on both
PROTAC degraders14−17 and allele-selective bump-and-hole
(B&H) targeting18−21 of the bromo and extra terminal (BET)
bromodomain proteins Brd2, Brd3, and Brd4. We describe the
structure-based design and development of cooperative
bumped PROTAC compounds designed to target a mutant
Brd4 bromodomain degron tag for the degradation of an
endogenously CRISPR-tagged target protein. Our best-in-class
degrader system is optimized in terms of degradation potency,
speed, and target selectivity, while showing no off-target
degradation of endogenous BET proteins and thus lacking
cytotoxicity, and is qualified as an appropriate chemical tool for
biological investigation in living cells and in vivo.
2. RESULTS AND DISCUSSION
2.1. Background and Design Rationale of the
BromoTag. To design the BromoTag, we hypothesized that
we could leverage our potent and selective BET bromodomain
recruiting PROTAC MZ1 (1, Figure 1A) and its target BET
bromodomain as a degron tag.14 Our extensive mechanistic
and structural characterization of MZ1 mode of action
highlighted that MZ1, with its VHL-bound E3 ligase, formed
the most stable, cooperative, and long-lived ternary complex
with the second bromodomain of Brd4 (Brd4BD2), despite
consisting of the pan-selective BET bromodomain ligand
(+)-JQ1 (3, Figure 1B). This preferential recruitment leads to
productive ubiquitination and preferential degradation of
endogenous Brd4.15,17,22,23 These findings suggested that
Brd4BD2 could provide an attractive degron tag for ligand-
induced degron technologies; however, the use of MZ1
Figure 1. (A) Pan-selective BET degraders, MZ1 and ARV-771. (B) Pan-selective BET inhibitors, (+)-JQ1 and I-BET762 (top). Allele-specific
bumped BET inhibitors, ME, ET, 9-ME-1, and 9-ET-1 (bottom). (C) Tailoring the “bump-and-hole” approach to BET bromodomains to produce
a high-affinity selective pairing that can be utilized as a degron system. (D) Conceptualization of the BromoTag degron approach.
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induces confounding downstream effects from its potent
induced degradation of all endogenous BET proteins.
To circumvent this limitation, we leveraged engineered
variants of BET bromodomains that we previously described,
which create a cavity (or “hole”) in the BET bromodomains
enabling allele-selective binding by a bulkier synthetic BET
ligand bearing a “bump”.18 Our previous, extensive work
developing such a “bump-and-hole” approach identified a Leu
residue in the ligand binding site, strictly conserved across all
BET family members. Using site-directed mutagenesis, the Leu
residue was mutated to a smaller Ala or Val to create a hole
that maintained domain stability and ligand-binding capacity.
Simultaneously, the pan-selective BET inhibitor I-BET762 (4,
Figure 1B) was modified by introducing a methyl or ethyl
“bump” to yield ME and ET (5 and 6, respectively, Figure 1B),
and later on 9-ME-1 and 9-ET-1 (7 and 8, respectively, Figure
1B), which differ by having a methoxy shift from the 8′ to 9′
position of the fused phenyl ring in the I-BET762 scaffold.18,20
The steric “bump” was accommodated into the newly formed
hole while clashing with the wild-type protein, allowing us to
engineer exquisite allele-selectivity within BET bromodo-
mains.18,20 We therefore reasoned that using such bumped
BET ligands, within the context of the MZ1 PROTAC
degrader, would enable selective degradation of target proteins
fused to a mutant Brd4BD2 domain, without detrimental
degradation of endogenous wild-type BET proteins. Such
bespoke “bump-and-hole”−PROTACs (B&H−PROTACs)
would therefore offer a complementary, generalizable system
of PROTAC-inducible degron tag technology.
2.2. Development of a Knock-In Cell Line with the
BromoTag Fused to Endogenous Brd2 Using CRISPR. To
establish the BromoTag platform and support the degrader
structure−activity relationships (SARs) to identify the best
compound, we sought a practical and simple system that
enables us to best optimize not only the degradation efficiency
but also the selectivity profile of our degraders. To this end, the
endogenous BET family protein Brd2 was chosen as a model
target due to the availability of a well-established antibody for
Brd2 detection, and the expression of a single protein isoform
detected as a single band in the western blot.24 Because Brd2
contains endogenous bromodomains and is degraded by 1 and
other BET PROTACs, we reasoned that a heterozygous
knock-in cell line allows us to monitor simultaneously both on-
target degradation (BromoTagged-Brd2) and of f-target degra-
dation (untagged Brd2) using the same antibody. Together
with the potential of f-target degradation of the other BET
proteins Brd3 and Brd4, this system thus enables us to best
monitor protein degradation selectivity. We therefore decided
to add the BromoTag at the N-terminus of the endogenous
Brd2 gene locus using CRISPR knock-in methodologies,
thereby yielding a chimeric protein bearing three bromodo-
mains (the exogenous BromoTag, in addition to the
endogenous Brd2BD1 and Brd2BD2). Hereafter, we refer to on-
target activity as the degradation of BromoTag-Brd2 and of f-
target activity as any degradation of either untagged Brd2 or
endogenous Brd3 or Brd4.
The BromoTag itself was designed based on our previous
work to develop a B&H strategy for BET family proteins.18 To
maximize our chances of producing a successful and
complementary degron for our MZ1-based B&H−PROTACs,
we chose to use Brd4BD2 L387A as the degron “BromoTag”
construct (comprising residues 368−440 of human Brd4, size
∼15 kDa, full amino acid sequence in Supporting Information
Figure S1). The specific bromodomain Brd4BD2 was chosen
because it forms the strongest and most cooperative ternary
complex with 1 and VCB (VHL/ElonginC/ElonginB),15
facilitating productive ubiquitination and rapid and potent
degradation of endogenous Brd4 by MZ1. Moreover, the
specific L387A mutation on Brd4BD2 was chosen instead of
L387V because it shows greatly reduced binding affinity for
acetylated histone tail partners compared to the wild-type or L-
V domain,20 suggesting that it would be less likely to introduce
unwanted neo functionality or protein−protein interactions
when used as a tag.
At the outset of the project, we chose HEK293 cells for our
CRISPR knock-in experiments to establish a model BromoTag
cell line due to their ease of transfection, good level of CRISPR
efficiency,10 and high level of expression of all the three BET
proteins. HEK293 cells were transfected simultaneously with
three plasmid constructs, two harboring cas9D10A which are N-
terminal Brd2-specific gRNAs. The other plasmid held the
knock-in sequence of the Brd4BD2 L387A BromoTag. The full
Figure 2. Design and development of a heterozygous knock-in BromoTag-Brd2 HEK293 cell line. (A) Design of the knock-in construct used in the
development of the CRISPR construct. (B) FACS single cell sort of HEK293 cells based on GFP expression. Successive single cells were sorted into
individual wells of a 96-well plate. (C) Junction PCR using genomic DNA of an expanded GFP-expressing clone paired against parental HEK293.
(D) Western blot demonstrating the selectivity of the polyclonal Brd4BD2L387A. antibody.
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knock-in construct contained in the 5′−3′ direction an eGFP
fluorescent marker, a P2A splice sequence followed sub-
sequently by the Brd4BD2 L387A sequence (Figure 2A, see
Supporting Information Figure S1 for full DNA sequences of
components). After transfection, the cells underwent fluo-
rescence-activated cell sorting (FACS) to identify GFP
expressing single cells denoting successful integration of the
knock-in construct (Figure 2B). The cells were expanded from
GFP expressing single cells, and an optimal heterozygous
knock-in clone was identified and chosen. A subsequent
junction PCR was undertaken, demonstrating successful
heterozygous integration of the BromoTag N-terminally to
Brd2 (Figure 2C and Supporting Information Figure S2). Since
HEK293 is a hypo-triploid cell line, we suspect that the
disparity in band intensity present in the junction PCR for the
wild-type over the knock-in cell line is due to single-allele
integration of our knock-in, leaving potentially two wild-type
non-modified alleles (Figure 2C). This heterozygous clone was
further validated via western blot using a Brd2 antibody and by
independently observing BromoTag-Brd2 expression using an
antibody against the BromoTag (Figure 2D and Supporting
Information Figure S3). This antibody was raised in-house
using a Brd4BD2L387A protein recombinantly expressed in
Escherichia coli as the antigen. This heterozygous BromoTag-
Brd2 HEK293 cell line was then subsequently genotyped,
showing successful in-frame knock-in of the eGFP-P2A-
BromoTag knock-in at the N-terminus of Brd2 (see
Supporting Information Figure S4). This cell line will now
be referred to as BromoTag-Brd2 HEK293 herein.
2.3. Development of First-Generation, I-BET762-
Based B&H−PROTACs. In order to combine both B&H
and PROTAC technologies, we set out to make an initial series
of B&H−PROTACs using MZ1 as a template and replacing its
BET targeting ligand with a variety of bumped I-BET762
derivatives we had previously developed.18,20 We first
inspected our ternary complex crystal structure between
Brd4BD2, 1, and VCB (Figure 3A) and superposed onto
Brd4BD2, the co-crystal structures of bumped I-BET chemical
probes 6 and 7 in complex with Brd2BD2 L383A (Figure 3B) and
Brd2BD2 L383V (Figure 3C), respectively. The chemical
structures of 1 and 6 (Figure 3B) and 1 and 7 (Figure 3C)
adopt a very similar binding mode, with the carbon adjacent to
the methyl ester bearing ethyl or methyl bump in 6 and 7,
respectively, aligning nicely with the non-bumped, bromodo-
main-binding portion of 1. With these structural insights, we
proceeded to synthesize the first-generation I-BET-based
B&H−PROTACs (Scheme 1).
We first reduced VH032-PEG3 azide 914 with a suspension
of 10% palladium on carbon in methanol under an atmosphere
of hydrogen gas to yield terminal amines which were then
coupled to racemic I-BET762-derived acids, 10−13, via
standard amide coupling conditions with 1-[bis-
(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-
pyridinium 3-oxid hexafluorophosphate (HATU), 1-hydroxy-
7-azabenzotriazole (HOAt), and diisopropylethylamine
(DIPEA) in dimethylformamide (DMF) or dichloromethane
(DCM) to yield bumped I-BET PROTACs, DAT487489
(15−17), and the non-bumped control, MZP-15 (14), each as
a mixture of two diastereomers (Scheme 1).
With this initial library in hand, we set out to evaluate the
activity and selectivity of our I-BET-based B&H−PROTACs
by treating our heterozygous BromoTag-Brd2 HEK293 cells
with 1 μM of compounds 15−17 or 1 μM of control
compounds MZP-15 (14), MZ1 (1), and cis-MZ1 for 6 h,
which is the sufficient time to achieve effective MZ1-induced
BET protein degradation (Figure 4A). The cells were
harvested, and the subsequent lysate was analyzed via western
blot using antibodies against BET proteins: Brd2, Brd3, and
Brd4 (Figure 4A). To our disappointment, none of the initial
B&H−PROTAC compounds induced detectable degradation
of the BromoTag-Brd2.
In understanding the potential reasons for the inactivity of
our initial set of compounds, we were curious to observe the
apparent significant lower activity of non-bumped 14 relative
to 1 across all the three BET family members (Figure 4A, see
Supporting Information Figure S5). While its presence as a
diastereomeric mixture may contribute to the lower apparent
activity of 14 compared to enantiomerically pure 1, we turned
our attention to the chemical structures of the two compounds.
Compounds 1 and 14 are otherwise structurally identical
except that they differ in the BET bromodomain binding
portion: 1 (JQ1-based) bears a dimethylthiophene group fused
to the diazepine ring, while 14 (I-BET762-based) bears an 8-
OMe-phenyl group in the equivalent position (cf. Figure 1B
and Scheme 1). We therefore turned to our structural
superposition between the ternary crystal structure Brd4BD2/
1/VHL and the binary structures of the bumped BET ligands
and inspected in more detail the region of the structures
around the different groups. This analysis revealed that the
methoxy group of the fused phenyl ring present in I-BET762-
Figure 3. (A) Ternary complex between Brd4BD2 (green, cartoon/
surface representation), MZ1 (1, stick, gray carbons), and VCB
(VHL: blue; elongin C: pink; elongin Bpale orange; and cartoon/
surface representations). Leu387 (stick, green) is indicated by an
arrow (PDB code: 5T35). Alignment of Brd4BD2 (pale green, cartoon
representation, 5T35) with (B) Brd2BD2 L383A (orange, cartoon
representation, 4QEW) and (C) Brd2BD2 L383V (yellow, cartoon
representation, 5O3C), co-crystallized with MZ1 (1, stick, gray
carbons), ET (6, stick, pink carbons), and 9-ME-1 (7, stick, blue
carbons), respectively. Brd4BD2 W.T. Leu387 (stick, pale green carbons)
and mutants Brd2BD2 L383A Ala383 (stick, orange carbons) and
Brd2BD2 L383V Val383 (stick, yellow carbons) are highlighted.
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derived ligands would clash with His110 present in VHL
(Figure 4B). The oxygen atom of the 8-OMe of 6 would be
∼3.0 Å away from the carbon atom between the two nitrogen
atoms of the His110 side chain, which is below the lower limit
for van der Waal’s interactions. We reasoned that such a
structural clash would destabilize the MZ1-like PROTAC
ternary complex, explaining the lower degradation activity of
the I-BET762-based compounds. This observation led to the
decision to replace the 8-OMe-phenyl group in the BET
binding portion of the PROTACs with the dimethyl-thiophene
group to develop compounds much more closely resembling
the full chemical structure of MZ1 as a design strategy to
minimize any potential disruption in the desired ternary
complex and enhance BromoTag degradation activity.
2.4. Development of Second-Generation, JQ1-Based
B&H−PROTACs. To overcome the limitations presented by
our I-BET762-based B&H−PROTACs, we next designed a
new set of eight JQ1-based compounds (Table 1). Around this
time in the development of the project, we learnt of another
BET targeting PROTAC, ARV-771 (2, Figure 1A),25 that is
structurally similar to 1 and also potently degrades the BET
proteins. Chemically, 2 consists of the same pan-selective BET
bromodomain ligand, (+)-JQ1 (3, Figure 1B), but differs from
1 by having a shorter, more lipophilic linker (minus
−CH2O−) and an extra benzylic methyl group in the VHL
ligand VH032,26 which is known to boost the VHL binding
affinity.27 To maximize the chemical diversity and hence our
chance to identify a potent BromoTag degrader, we designed
four bumped PROTAC compounds based on 1 and four based
on 2.25 For each set of four, two compounds would contain
either a more sterically conserved methyl bump or a more
sterically demanding ethyl bump. Each methyl- or ethyl-
bumped BET bromodomain ligand would then be conjugated
to the linker via an amide bond to resemble the parent
compound or via an ester bond. Our reasoning for choosing
the less conventional ester conjugation was based on our
previous observation that bumped BET ligands bearing an
ester group adjacent to the alkyl bump group were significantly
more stable compared to their parent non-bumped ana-
logues.20
To synthesize our bumped JQ1 ligands, we adapted the
route described by Filippakopoulos et al. and utilized the late-
stage alkylation described by Baud et al. and Runcie et al.
(Scheme 2).18,20,28 First, (±)-Fmoc-Asp(OMe)-OH (26) was
treated with thionyl chloride in DCM and converted to the
acid chloride before being refluxed with aminoketone 27 in
chloroform to form an “open” amide Fmoc-protected
intermediate. This “opened” intermediate is then refluxed in
triethylamine to remove the Fmoc protecting group and reveal
the free amine, which in the presence of acetic acid, ring-closes
to form the thieno-1,4-diazepine, 28. Deprotonation of amide
28 with potassium tert-butoxide in the presence of diethyl
chlorophosphate, followed by treatment with acetylhydrazine,
forms the methyltriazole ring and yields triazolothienodiaze-
pine (±)-JQ1-OMe (29) as a racemic mixture.
Scheme 1. Synthesis of I-BET762-Based B&H−PROTACs and Non-bumped Control Compounda
aReaction conditions: (a) 10% Pd/C, H2, MeOH, r.t., and 3 h; (b) 10, HATU, DIPEA, DCM, r.t., and 18 h; and (c) bumped I-BET acid 11, 12, or
13; HATU; HOAt; DIPEA; DMF; r.t.; and 18 h. * indicates relative configuration at the specified stereogenic centers in the molecule.
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To introduce either methyl or ethyl bump, 29 was
deprotonated with potassium hexamethyldisilazane
(KHMDS) at −78 °C in tetrahydrofuran (THF). The
subsequent enolate was then treated with either methyl or
ethyl iodide to yield racemic bumped JQ1-OMe derivatives
30a and 30b or 31a and 31b, respectively, as mixtures of
diastereomers, which were easily separated using high-
performance liquid chromatography (HPLC). Methylation
proceeded with a diastereomeric ratio (d.r.) of 1:4 for the
desired (2S*,3R*) isomer to the undesired (2S*,3S*) isomer.
Ethylation proceeded with a d.r. of 1:1.5. The undesired
(2S*,3S*) isomers, 30b and 31b, can be epimerized by treating
with sodium methoxide in methanol under microwave
irradiation to yield a further 1:1 mixture of diastereomers,
which, following HPLC separation, yields more of the desired
(2S*,3R*) isomers 30a and 31a.
To allow for further functionalization and linker conjugation,
methyl esters 30a and 30b were hydrolyzed under mild
conditions with lithium hydroxide in THF and water to yield
the conjugatable carboxylic acids 32 and 33 as racemic
mixtures (Scheme 2).
The next step was to connect linkers 36 and 37 to the
VH032-amine, 34, and linkers 38 and 39 to the methylated
VH032-amine, 35, under standard amide coupling conditions
with HATU and DIPEA in DMF to yield amides 9, 40, 42, and
43 (Scheme 3). Silylethers, 40 and 43, were cleaved using a
solution of tetrabutylammonium fluoride (TBAF) in THF to
yield terminal alcohols 41 and 44, respectively, as suitable
precursors for ester conjugation.
Azides, 9 and 42, were subsequently reduced with a
suspension of 10% palladium on carbon in methanol under
an atmosphere of hydrogen gas to yield terminal amines before
being coupled to racemic bumped JQ1 acids, 32 and 33, using
(1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate (COMU) and
DIPEA in THF to yield amide B&H−PROTACs, 18−21 as
a mixture of diastereomers (Scheme 4).
Finally, alcohols 41 and 44 were coupled to bumped JQ1
acids, 32 and 33, with N-(3-dimethylaminopropyl)-N′-ethyl-
carbodi imide hydrochlor ide (EDC ·HCl) and 4-
(dimethylamino)pyridine (DMAP) in THF to yield ester
B&H−PROTACs, 22−25, as a mixture of two diastereomers
(Scheme 4). The diastereomers formed in each amide and
ester case were inseparable by HPLC and were progressed as
diastereomeric mixtures for preliminary in cellulo evaluation to
screen for BromoTag-Brd2 degradation and selectivity over
wild-type BET proteins.
We evaluated the cellular activity of all eight B&H−
PROTACs (18−25) in our heterozygous BromoTag-Brd2
knock-in HEK293 cell line at concentrations ranging from 1
nM to 10 μM (Figure 5). Strikingly, all compounds showed a
pronounced effect on the degradation of the BromoTag-Brd2
isoform, achieving observable and in most cases complete
depletion of BromoTagged-Brd2 protein. This allowed
quantitative analysis of the compounds’ on-target degradation
potency (DC50) and efficacy (Dmax) to build SAR, with
quantification performed via detection using both independent
antibodies, which compared extremely well in all cases (Table
2).
The best compounds emerged to be 19, 23, and 25, which
all harbor an ethyl bump. They showed both potent and
complete degradation of the BromoTag-Brd2 isoform, with
DC50 values of 250−360, 13−80, and 13−16 nM, respectively,
and Dmax >75%. Importantly, no observable of f-target
degradation of the untagged Brd2 or the other endogenous
BET proteins was observed, except minor off-target degrada-
tion of Brd3 observed with 25 at 1 μM (Figure 5, see
Supporting Information Figures S6−S8), suggesting that these
compounds successfully enable highly selective BromoTag
degradation. Interestingly, at higher concentrations of 1−10
μM (Figure 5, see Supporting Information Figures S6−S8),
esters 23 and 25 showed a strong onset of the hook effect, a
well-known phenomenon with bifunctional PROTAC de-
graders where binary interactions between PROTAC/target
and PROTAC/E3 ligase outcompete productive ternary
complex formation.29 In contrast, no hook effect was observed
with amide 19. The last ethyl-bumped compound, 21, showed
the least complete (Dmax < 70%) and weakest (DC50 ∼ 1 μM)
degradation activity, with a very narrow degradation window
also due to strong hook effect at 10 μM.
All methyl-bumped compounds 18, 20, 22, and 24 also
showed strong on-target degradation activity and were on
average 2-fold more potent than their ethyl-bumped counter-
parts, with DC50s values between 100 and 160, 320 and 400,
20 and 80, and 5 and 10 nM, respectively. However, we
observed that all methyl-bumped compounds also induced
undesired of f-target degradation, thus showing poor selectivity.
Figure 4. First-generation IBET-762-based B&H−PROTACs are
inactive against BromoTag-Brd2 due to the proposed steric clash in
the MZ1-like ternary complex. (A) Western blot data for BET protein
levels after the treatment of PROTAC over 6 h in heterozygous
BromoTag-Brd2 HEK293 cells. (B) Alignment of the ternary complex
between Brd4BD2 (green, surface representation), MZ1 (1, stick, gray
carbons), and VHL (cyan, surface representation) (PDB code: 5T35),
with ET (6, 8-OMe, stick, pink carbons, 4QEW) and 9-ME-1 (7, 9-
OMe, stick, blue carbons, 5O3C) to show the potential clash with
VHL by the bulkier 8/9-methoxyphenyl group. His110 is highlighted
(stick, cyan carbons).
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These results suggest that the methyl group does not provide
enough of a steric clash with the conserved Leu residue of the
wild-type BET proteins, and that it is much more tolerated
than the larger ethyl bump and so is not sufficient to dial out
of f-target degradation. Since selectivity against endogenous
BET protein is a strictly required criterion for a successful
BromoTag system, we decided to drop all methyl-bumped
compounds at this stage.
It is interesting to note that all esters (22−25) are more
potent than their respective amide counterparts (18−21) by
between 2- and 126-fold in DC50 (Table 2). Recently, we have
shown that the amide-to-ester substitution can provide a
simple strategy to increase the PROTAC degradation activity
due to increased lipophilicity and cellular permeability while
maintaining remarkable intracellular stability.30 This trend is
well reflected in this compound set, as all esters (22−25) were
cell-active and showed more potent DC50 and a prominent
hook effect at the higher concentrations compared to their
amide counterparts.
Taken together, the results from this screen identified three
compounds, ET-MZ1 (19), ET-OMZ1 (23), and ET-OARV-
771 (25) as the most selective BromoTag-Brd2 degraders,
meeting criteria for potent on-target activity while largely
sparing of f-target BET degradation. We therefore took these
three compounds forward in the pipeline.
2.5. Synthesis of ET-OMZ1, ET-OARV-771, and ET-
MZ1 as Single Stereoisomers. We realized that our second-
generation B&H−PROTACs, while displaying encouraging
results, were all synthesized as diastereomeric mixtures,
indicating that they would not only contain the active species
but also contain an inactive or less-active species that would be
expected to lead to an apparent weaker activity and a narrower
selectivity window of the compounds. To gain a true
degradation profile of the biologically active isomers
(eutomers), we next sought to synthesize our current best
degraders as enantiomerically pure, single diastereomers. To
achieve enantiomerically pure PROTACs, we developed a new
stereoselective synthesis to bumped BET ligands, which we
disclosed recently.21 In brief, our novel stereoselective route
allowed us to incorporate the alkyl bump much earlier in the
synthesis of the BET-ligand scaffold. To achieve this, we
optimized a lithium hexamethyldisilazane (LHMDS)-medi-
ated, diastereoselective alkylation of a di-protected aspartate
derivative and took this through to final bumped JQ1 acid
Table 1. Target JQ1-Based B&H−PROTAC Library
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analogues with complete retention of stereochemistry and in
>99% ee.21 At this stage in the project, we therefore decided to
use the enantiomerically pure ET-JQ1-OH (45) to prepare
new B&H−PROTACs, AGB1 (46), AGB2 (47), and AGB3
(48) (Scheme 5).
For esters 46 and 47, acid 45 was converted quantitatively to
an acid chloride intermediate with thionyl chloride in DCM
and was subsequently reacted with alcohols 41 and 44 to yield
final compounds 46 and 47 as single stereoisomers. For amide
48, azide 9 was first reduced with a suspension of 10%
palladium on carbon in methanol under an atmosphere of
hydrogen gas to yield the intermediate amine which was
immediately coupled to 45 using COMU and DIPEA in DMF
to yield 48 as a single stereoisomer.
We next evaluated the cellular activity of 46−48 using our
BromoTag-Brd2 knock-in cell line as described before (Figure
6A,C and Table 3). At this stage, we decided to quantify
protein degradation over a wider eight-point concentration
range from 10 μM to 1 nM for the purpose of obtaining more
accurate DC50 and Dmax values. Each compound displayed
potent, highly selective, and near-complete (Dmax > 92%)
degradation of BromoTag-Brd2 over the endogenous BET
proteins. Both esters 46 (DC50 13−15 nM) and 47 (DC50 1−3
nM) showed more potent on-target degradation activity than
amide 48 (DC50 210−290 nM), corresponding to >17-fold
and >81-fold lower DC50, respectively (Figure 6A,C, Table 3,
and see Supporting Information Figures S9−S14). As
predicted, the enantiomerically pure compounds were found
to be on average 5-fold more potent and displayed much more
complete on-target degradation than when they were tested as
diastereomeric mixtures (cf. 23, 25, and 19, respectively, Figure
5, Table 2). The large difference in potency displayed by the
esters is exemplified by the pronounced hook effect at
concentrations >1 μM. From our recent work on amide-to-
ester substitutions in related non-bumped BET PROTACs, the
increase in potency observed is most likely due to the increase
in cellular permeability as a result of increased lipophilicity
from switching from an amide in 48 to an ester in 46.30
To assess the speed at which our B&H−PROTACs were
able to fully deplete BromoTag-Brd2, we next ran a time-
dependent degradation assay by treating heterozygous
BromoTag-Brd2 HEK293 cells with 500 nM 46 or 47, or 1
μM 48, and measuring BromoTag-Brd2 protein levels over 36
h (Figure 6B,D, Table 3, and see Supporting Information
Figures S15 and S16). Compound 46 proved to be the most
rapid and most complete degrader that is able to completely
degrade BromoTag-Brd2 within 6 h, yielding a protein half-life
(t1/2) of just 40 min. Compound 48 was a slightly slower
degrader, inducing a protein t1/2 of 113 min and was only able
to degrade up to ∼80% of the protein in this experiment
(Figure 6D). That is, the use of 48 twice the treatment
concentration of 46 clearly demonstrates the more potent,
faster, and profound activity of the ester-bumped PROTAC.
The other ester compound 47 showed near-complete target
degradation, similar to 46, but not as fast (t1/2 = 142 min)
when compared with 46, which combined with the residual,
albeit minor off-target degradation of Brd3 at 100−1000 nM
(Figure 6), led us to deprioritize 47. Together, the cellular data
suggest 46 as the best degrader among the three evaluated as
single stereoisomers.
To better understand the mode of action of our three
B&H−PROTACs, we next sought to investigate the ability of
each compound to form a ternary complex between
recombinantly purified Brd4BD2 L387A bromodomain protein
and VHL. We therefore employed a competitive fluorescence
polarization (FP) assay as previously published,17,31−33 where
we displace a fluorescently labeled HIF-1α peptide probe
bound to VHL by titrating either the compound alone (for
Scheme 2. Synthesis of Racemic Bumped JQ1 Ligandsa
aReaction conditions: (a) (i) SOCl2, DCM, reflux, and 2 h; (ii) 27, CHCl3, reflux, and 1 h; (iii) TEA, reflux, and 16 h; and (iv) AcOH, 1,2-DCE,
80 °C, and 1 h; (b) (i) KOtBu, THF, −78 to −10 °C, and 30 min; (ii) (EtO)2P(O)Cl, −78 to −10 °C, and 45 min; (iii) AcNHNH2, r.t., and 1 h;
(iv) n-BuOH, 90 °C, and 1 h; (c) (i) KHMDS, THF, −78 °C, and 1 h; (ii) MeI/EtI, −78 °C to r.t., and 16 h, and (iii) HPLC separation; (d) (i)
NaOMe, MeOH, 120 °C m.w., and 40 min and (ii) HPLC separation; and (e) LiOH, THF/H2O 4:1, 30a, r.t., 48−72 h, 30b, 45 °C, and 1 wk. *
indicates relative configuration at the specified stereogenic centers in the molecule.
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binary binding) or by titrating the compound preincubated
with Brd4BD2 L387A protein (for ternary complex binding). The
cooperativity (α) of ternary complex formation can then be
determined (α = Kd
binary/Kd
ternary) (Figure 7). A ternary
complex is said to have positive or negative cooperativity
when α > 1 or α < 1, respectively, and not cooperative when α
= 1. PROTACs 46, 47, and 48 had equipotent ternary binding
affinity (Kd = 11, 12, and 9 nM, respectively), with MZ1-based
46 and 48 giving the most cooperative ternary complexes (α =
11.1 and 10.9, respectively). ARV-771-based 47 formed the
least cooperative ternary complex (α = 3.6, Figure 7B) due to
its 2−3 fold greater binary affinity to VHL (Kd = 45 nM for 47,
compared to Kd = 125 and 102 nM for 46 and 48,
respectively). This loss in ternary complex cooperativity and
stability is likely contributing to the slower rates of degradation
observed, consistent with the previous findings with BET
PROTACs.17,23,34
With all this biological data taken together, we selected 46 as
our best B&H−PROTAC and decided to take this forward for
further biological evaluation.
2.6. Further Biological and Mechanistic Character-
ization of AGB1. Having established AGB1 (46) as the best
potent and selective degrader compound for our BromoTag
system, we next sought to further characterize its mechanism of
action as expected for this compound class. To demonstrate
that the on-target degradation activity of 46 is mechanistically
due to its PROTAC mode of action, we performed
pharmacological competition experiments (Figure 8A, see
Supporting Information Figure S17). To demonstrate VHL
and proteasome dependency, we pretreated with the NAE1
inhibitor MLN4924, which inhibits neddylation of cullin 2,35
with the VHL inhibitor VH298,36 and with the proteasome
inhibitor MG132.37 In addition, to demonstrate that the on-
target activity on BromoTag-Brd2 is due to the recruitment of
the BromoTag, we pretreated with ET-JQ1-OMe, which binds
with high affinity to the Brd4BD2 L387A variant (Kd = 65 nM) but
exhibits undetectable binding to the wild-type domain.21 In
this experiment, we separately exposed our heterozygous
BromoTag-Brd2 HEK293 cells to the different inhibitors for a
short 1 h prior to subsequent treatment with 200 nM 46 before
continuing treatment for a further 3 h to minimize potential
confounding effects due to inhibitor cytotoxicity. As expected,
the on-target degradation activity by 46 was completely
abrogated upon pretreatments with MLN4924 or VH298,
demonstrating dependency on CRL2VHL activity (Figure 8A
and see Supporting Information Figure S17). The cellular
activity of MLN4924 and VH298 in this experiment was
confirmed by observing significant accumulation of HIF-1α
and blockade of Cul2 neddylation upon MLN4924 treatment.
The on-target degradation activity was shown to be
proteasome-dependent as it was blocked upon pretreatment
with MG132. A similar outcome was also seen from the
pretreatment with ET-JQ1-OMe (Figure 8A and see
Supporting Information Figure S17), confirming that the on-
target degradation is exquisitely driven by target engagement
with the BromoTag and not contributed by potentially
Scheme 3. Conjugation of Linkers to VHL Ligandsa
aReaction conditions: (a) HATU, DIPEA, DMF, r.t., and 2 h and (b) TBAF, THF, r.t., and 6 h.
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adventitious weaker recruitment of the wild-type bromodo-
mains of the endogenous Brd2 protein.
We next sought to monitor the duration of the on-target
degradation activity of 46 using washout experiments.
BromoTag-Brd2 HEK293 cells were treated with 200 nM 46
for 3 h and rinsed twice with phosphate-buffered saline (PBS),
and fresh media were replenished without PROTAC.
Following complete depletion after 3 h, the protein levels of
BromoTag-Brd2 were shown to recover 24 h after washout
(Figure 8B and see Supporting Information Figure S18). This
effect was in stark contrast to the complete and durable on-
target degradation for up to 72 h without washout. This result
confirms the reversible nature of our BromoTag system.
Noticeably, the Brd2 expression begins to decline 24 h after
recovery, possibly reflecting the long-term regulation of Brd2
protein levels.
To qualify our degrader 46 as a suitable chemical probe for
cellular biological investigation, we considered it important to
assess potential cytotoxicity that might confound biological
effects and responses and mask the desired on-target
pharmacology. To this end, we elected as probe criteria that
the compound does not exhibit any cytotoxicity at around and
up to 10-fold higher than the concentrations at which it is to be
used in cells. The remarkable selectivity and lack of of f-target
BET degradation activity of 46 encouraged us that the
compound should not be cytotoxic, yet we decided to test this
in the parent HEK293 cells, as well as more BET-sensitive MV-
4-11 and 22RV1 cell lines. To enable a suitable control to
discount any potential non-degrading off-target engagement
activity, we synthesized compound cis-AGB1 (52) bearing the
cis- instead of trans-hydroxyproline group to abrogate binding
to VHL (Scheme 6), a well-established strategy to yield
negative non-degrading control compounds.14 To monitor cell
viability, HEK293, MV-4-11, and 22RV1 cells were plated in a
96-well plate format and treated with vehicle control (DMSO),
46, its non-degrading control (52), and their non-bumped
control compounds MZ1 and cis-MZ1, as well as the positive
control cytotoxic agent staurosporine, in a dose-dependent
manner and up to 10 μM. Cellular ATP levels as a proxy of
viable cells were then measured using a CellTiter-Glo 2.0 cell
Scheme 4. Synthesis of JQ1-Based B&H−PROTACs as Mixtures of Two Diastereomersa
aReaction conditions: (a) 10% Pd/C, H2, MeOH, r.t., and 3 h; (b) bumped JQ1 acid (32 or 33), COMU, DIPEA, THF, r.t., and 4 h; and (c)
bumped JQ1 acid (32 or 33), EDC·HCl, DMAP, THF, r.t., and 16 h. * indicates relative configuration at the specified stereogenic centers in the
molecule.
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viability assay (Figure 8C). Reassuringly, and as expected, 46
showed lack of cytotoxicity up to high concentrations of 1−10
μM in all the three cell lines. The remarkable sparing of of f-
target degradation of endogenous BET proteins by 46 is starkly
evidenced by comparing it with MZ1 (EC50 of ∼20 nM) in the
highly BET-sensitive MV-4-11 cells. Together, this data
qualifies 46 as a mechanistically clean and bona fide BromoTag
degrader for cellular investigation.
After demonstrating that 46 and 52 are non-toxic even in
BET-sensitive cell lines, we next sought to evaluate their
cellular selectivity at the proteome-wide level. To do this, we
subjected our heterozygous BromoTag-Brd2 HEK293 cell line
to a 1 μM treatment of 46, its non-degrading control 52, or
vehicle (DMSO) for 2 h prior to harvest. The harvested lysate
was then subjected to multiplexed tandem mass tag (TMT)
labeling mass spectrometry to enable quantitative and unbiased
analysis of protein levels in each condition. Among the 6621
proteins quantified from this analysis, only Brd2 was shown to
be significantly degraded upon 1 μM treatment with 46. No
significant degradation was observed for any of the 6621
proteins upon treatment with 1 μM of 52 (Figure 9 and see
Supporting Information Figure S19). Together, this data
further confirms the exquisite selectivity of compound 46 for
the hole-bearing BromoTag over not only wild-type BET
proteins but also the wider cellular proteome more broadly,
further establishing the BromoTag as a utilizable approach for
the highly tailored and selective cellular investigation of target
proteins.
Figure 5. Biological evaluation of second-generation B&H−PROTACs in BromoTag-Brd2 HEK293 cells. Western blot data for BET protein levels
monitored from 10 μM to 1 nM compound treatment over 6 h in heterozygous BromoTag-Brd2 HEK293 cells. Bands are normalized to tubulin
and negative control (cis-MZ1) to derive DC50 values that enable the rank order of each PROTAC.
Table 2. Quantification of the Degradation Profile of
Second-Generation B&H−PROTACs against
BromoTagged-Brd2 via Two Different Antibodies (Ab)
Ab: Brd4BD2 L387A Ab: Brd2
compound pDC50
a Dmax (%) pDC50
a Dmax (%)
ME-MZ1 (18) 6.8 ± 0.1 90 7.0 ± 0.2 92
ET-MZ1 (19) 6.6 ± 0.6 76 6.5 ± 0.2 80
ME-ARV-771 (20) 6.5 ± 0.4 70 6.4 ± 0.6 60
ET-ARV-771 (21) 6.1 ± 0.3 69 5.7 ± 1.8 51
ME-OMZ1 (22) 7.1 ± NA 94 7.7 ± 0.1 96
ET-OMZ1 (23) 7.1 ± NA 90 7.9 ± 0.2 96
ME-OARV-771 (24) 8.0 ± NA 91 8.3 ± 0.1 91
ET-OARV-771 (25) 7.9 ± 0.2 90 7.8 ± 0.3 85
aCalculated as mean (±S.E) from three independent biological
experiments.
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To qualify 46 as not only an all-cellular but also as an in vivo
suitable degrader probe, we next evaluated the plasma stability
of 46 by incubating in mouse plasma at 37 °C and measuring
the levels of 46 remaining at several time points over 1 h
(Figure 10A). 46 showed excellent plasma stability with no
significant changes to levels of 46 throughout the experiment.
Finally, to further qualify 46 as appropriate for in vivo studies,
we assessed its pharmacokinetic (PK) profile in mice (Figure
10B and Tables 4 and 5). 46 was shown to have good PK
profiles in mice for both intravenous (IV) (Table 4) and
subcutaneous (SC) (Table 5) 5 mg/kg injections. 46 has
comparable PK profiles as seen for parent compound MZ1 (1)
with a relatively low clearance rate (CL) of 47.2 mL/min/kg
and good half-lives (T1/2) of 1.49 and 1.65 h in IV and SC,
respectively (compared with 1.05 and 2.95 h for 1) (Tables 4
and 5).38 Strikingly, 46 was able to maintain a plasma
concentration above its BromoTag-Brd2 DC50, 6h of ∼13 nM
when dosed at 5 mg/kg for ∼4 h IV injection and for >8 h SC
injection (Figure 9), making it suitable for in vivo studies to
assess the functional consequences of BromoTagged target
protein degradation in genetically engineered mouse models.
3. CONCLUSIONS AND FUTURE PERSPECTIVE
Through a careful structural guided design, we have developed
AGB1 (46) and qualified it as a fast, highly selective, and
potent B&H−PROTAC degrader for our new inducible
degron system, BromoTag. We show that AGB1 (46) not
only forms a strong, cooperative ternary complex between
VHL and the BromoTag (Brd4BD2 L387A) but also completely
degrades BromoTagged target proteins with low nanomolar
potency and exquisite selectivity over the native wild-type BET
proteins at the proteome-wide level. We also show that AGB1
(46) is not cytotoxic in several cancer relevant cell lines,
further exemplifying its superior selectivity over of f-target
endogenous BET proteins. AGB1 (46) has also shown
excellent plasma stability and acceptable PKs for it to be
suitable for later in vivo studies in mouse models. We therefore
qualify AGB1 (46) and our new BromoTag system as a useful
tool to probe biology. Demonstrated and optimized here
through N-terminal tagging of the target protein Brd2, future
work will focus on exemplifying feasibility to use the
BromoTag on multiple targets, including tagging proteins at
the C-terminus as well, and applying the technology to address
targeted biological questions in cells and in vivo. We envisage
that the BromoTag could also be used in tandem with other
inducible degrons such as dTAG, AID, or HaloPROTACs as
an orthogonal system to individually or simultaneously deplete
more than one protein at once.
During the preparation of this manuscript, a report came out
online describing the development of XY-06-007, a compound
that utilizes the same B&H−PROTAC concept used to
develop AGB1.39 Although AGB1 and XY-06-007 were not
compared in the same assays, our data suggests that the MZ1-
like highly cooperative and stable ternary complex formed by
AGB1 with VHL and our BromoTag underscores its fast,
profound and selective tagged target protein degradation that
is more significant with AGB1 than XY-06-007. In future, it will
be interesting to compare the degradation potencies, kinetics,
and potential for off-target degradation activity of the two
compounds side-by-side against CRISPR-tagged target pro-
teins expressed at the near-endogenous level, as shown here.
Because XY-06-007 and AGB1 differ significantly both in the
Scheme 5. Synthesis of Enantiomerically Pure AGB1, AGB2, and AGB3a
aReaction conditions: (a) (i) SOCl2, DCM, r.t., and 3 h; (ii) 41 or 44, DCM, r.t., and 16 h; (b) 10% Pd/C, H2, MeOH, r.t., and 3 h; and (c) 45,
COMU, DIPEA, DMF, r.t., and 2 h.
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chemistry (I-BET762 rather than JQ1-based methyl rather
than ethyl bump, respectively) and biology (CRBN- rather
than VHL-based, Brd4BD1 L94V tag instead of Brd4BD2 L387A,
respectively), the two approaches can be highly complemen-
tary. Therefore, the work described herein and that of Nowak
et al.39 provide two distinct methods to induce degradation of
bromodomain-tagged proteins, which add to the growing
arsenal of inducible degron technologies available to study the
effect and implications of rapid and highly selective
degradation of a target protein.
4. EXPERIMENTAL SECTION
4.1. Chemistry. 4.1.1. Synthesis. Chemicals, commercially
available, were purchased from Apollo Scientific, Sigma-Aldrich,
Fluorochem, or Manchester Organics and used without any further
purification. All reactions were carried out using anhydrous solvents.
The reactions were monitored using either an Agilent Technologies
1200 series analytical high-performance liquid chromatograph
(HPLC) connected to an Agilent Technologies 6130 quadrupole
LC/MS containing an Agilent diode array detector and a Waters
XBridge C18 column (50 mm × 2.1 mm and 3.5 μm particle size).
The samples were eluted with a 3 min gradient of 5−95% MeCN/
water containing 0.1% formic acid at a flow rate of 0.7 mL/min or a
Shimadzu HPLC/MS 2020 with a photodiode array detector and a
Hypersil Gold column (1.9 μm 50 × 2.1 mm). The samples were
eluted with a 3 min gradient of 5−95% MeCN/water containing 0.1%
formic acid at a flow rate of 0.8 mL/min. The intermediates were
purified by flash column chromatography using a Teledyne Isco
Figure 6. Biological evaluation of AGB1 (46), AGB2 (47), and AGB3 (48) in BromoTag-Brd2 HEK293 cells. (A) Western blot data for BET
protein levels monitored from 10 μM to 1 nM compound treatment over 6 h in heterozygous BromoTag-Brd2 HEK293 cells. (B) Time course
western blot data of Brd2 levels in heterozygous BromoTag-Brd2 HEK293 cells upon 500 nM treatment of 46 and 47 and 1 μM treatment of 48
over 36 h. (C,D) Plots to calculate (C) DC50 and (D) t1/2 values for compounds enabling determination that AGB1 is the best choice for further
validation. Western blots from (A,B) were normalized to tubulin and compared to a vehicle control (DMSO) to derive pDC50 or t1/2 values that
enable rank order of each PROTAC.
Table 3. Degradation Profile for AGB1, AGB2, and AGB3









AGB1 (46) 7.8 ± 0.2 99 7.9 ± 0.1 97 40 ± 15
AGB2 (47) 9.0 ± 0.4 100 8.6 ± 0.2 98 142 ± 13
AGB3 (48) 6.5 ± 0.3 92 6.7 ± 0.1 96 113 ± 8
aCalculated from the mean (±S.E.) of two independent repeats.
bCalculated from the mean (±span) of two independent repeats.
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Figure 7. FP of B&H−PROTAC binary and ternary complex binding. Binary and ternary complex formation FP data for 46 (A), 47 (B), and 48
(C) to VHL alone (black solid line) or preincubated with Brd4BD2 L387A to VHL (colored dashed line), respectively. Error bars and Kd values are
mean (±S.E.M.) from N = 4 for binary and ternary binding to VHL. The left shift between the binary and ternary data indicates positive
cooperativity. Cooperativity (α) calculated as a ratio of Kd
binary/Kd
ternary.
Figure 8. Cellular mechanistic characterization of AGB1 (46) degradation activity. (A) Western blot illustrating the on-target degradation activity
of 46 is dependent on the activity of CRL2VHL and proteasome and on BromoTag target engagement. BromoTag-Brd2 HEK293 cells were treated
with 200 nM 46 (3 h) following pretreatment (1 h) with the proteasome inhibitor MG132, neddylation inhibitor MLN4924, VHL inhibitor
VH298, or BromoTag inhibitor ET-JQ1-OMe or DMSO vehicle. (B) Western blots demonstrating the recovery of BromoTag-Brd2 post-removal
of 200 nM 46 after a 3 h treatment in heterozygous BromoTag-Brd2 HEK293 cells. Control experiments for no-wash and vehicle treatments are
included. Bands are normalized to tubulin protein levels and compared to a vehicle control (DMSO) to quantify the final protein levels of
BromoTag-Brd2. (C) Effect on antiproliferation of 46 compared to MZ1 and non-degrader controls 52 and cis-MZ1. Staurosporine was used as a
positive control for cytotoxicity. MV-4-11, 22Rv1, and HEK293 cells were treated with varying concentrations of compound, and after 24, 48, and
48 h, respectively, the cells were subjected to the Promega CellTiter-Glo cell viability assay. The pEC50 values (±S.E.M) are mean from N = 2 for
MV-4-11 and 22Rv1 cells and N = 3 for HEK293 cells from data normalized from vehicle control (DMSO).
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CombiFlash Rf or Rf200i with Normal Phase RediSep Rf Disposable
Columns or with Reverse Phase RediSep Rf Gold C18 Reusable
Columns. Final compounds were purified by HPLC using a Gilson
Preparative HPLC System equipped with a Waters X-Bridge C18
column (100 mm × 19 mm and 5 μm particle size) using a gradient
from 5 to 95% of acetonitrile in water containing 0.1% formic acid or
ammonia over 10 min at a flow rate of 25 mL/min unless stated
otherwise. Compound characterization using NMR was performed
either on a Bruker 500 Ultrashield or on a Bruker Ascend 400
spectrometer. The proton (1H) and carbon (13C) reference solvents
used are as follows: d1-chloroformCDCl3 [(δH = 7.26 ppm/δC =
77.15 ppm)] and d4-CD3OD (δH = 3.31 ppm/δC = 49.00 ppm).
Signal patterns are described as singlet (s), doublet (d), triplet (t),
quartet (q), quintet (quint.), multiplet (m), broad (br), or a
combination of the listed splitting patterns. The coupling constants
(J) are measured in hertz (Hz). The NMR spectra for all compounds
were obtained using Bruker TopSpin 4.1.1. High-resolution mass
spectrometry (HRMS) was performed on a Bruker MicrOTOF II
focus ESI Mass Spectrometer connected in parallel to a Dionex
Ultimate 3000 RSLC system with a diode array detector and a Waters
XBridge C18 column (50 mm × 2.1 and 3.5 μm particle size). The
samples were eluted with a 6 min gradient of 5−95% acetonitrile/
water containing 0.1% formic acid at a flow rate of 0.6 mL/min. All
compounds are >95% pure by HPLC.
4.1.2. General Procedure A. Azide 9 (synthesized according to the
literature14) (1 equiv) was dissolved in MeOH (125 mL/mmol). A
catalytic amount of 10 wt % Pd/C was added, and the reaction was
stirred under an atmosphere of H2 for 3 h. The reaction mixture was
then filtered through PTFE syringe filters and evaporated to dryness
to obtain the desired amine quantitative yields. The resulting amine
(1 equiv) was added to a solution of acid (1 equiv), HATU (1 equiv),
HOAt (1 equiv), and DIPEA (3 equiv) in DCM or DMF (2 mL) and
left to stir at r.t. for 18 h. This was then purified by HPLC.
4.1.3. General Procedure B. Azides (1 equiv) were dissolved in
MeOH (125 mL/mmol). A catalytic amount of 10 wt % Pd/C was
added, and the reaction was stirred under an atmosphere of H2 for 3
h. The reaction mixture was then filtered through PTFE syringe filters
and evaporated to dryness to obtain the desired amines’ quantitative
yields. The resulting amines were added to a solution of alkylated JQ1
acids (1 equiv), COMU (1.5 equiv), and DIPEA (3 equiv) in THF (8
mL/mmol) and stirred at r.t. for 4 h. The mixtures were then
concentrated in vacuo, and the residues were purified by HPLC using
a linear gradient of 5−95% MeCN in 0.1% formic acid in water over
12 min to afford amides as mixtures of two diastereomers.
4.1.4. General Procedure C. Alkylated JQ1 acids (1 equiv) and
EDC·HCl (2 equiv) were dissolved in THF (15 mL/mmol) and
stirred at r.t. for 5 min. DMAP (3 eq) and alcohols (2 equiv) were
then added, and the reaction was left to stir at r.t. for 16 h. The
mixtures were then concentrated in vacuo, and the residues were
purified by HPLC using a linear gradient of 5−95% MeCN in 0.1%
formic acid in water over 12 min to afford amides as mixtures of two
diastereomers.
4.1.5. General Procedure D. Compound 29 (120 mg, 0.29 mmol)
was dissolved in THF (5.2 mL) and cooled to −78 °C. A solution of
0.5 M KHMDS in toluene (812 μL, 0.41 mmol) was added dropwise,
Scheme 6. Synthesis of Negative Control cis-AGB1 (52)a
aReaction conditions: (a) 37, COMU, DIPEA, DMF, r.t., and 2 h; (b) TBAF, THF, r.t., and 6 h; and (c) (i) 45, SOCl2, DCM, r.t., and 3 h and (ii)
51, DCM, r.t., and 16 h.
Figure 9. Proteomics of AGB1 (46) and cis-AGB1 (52) treated
heterozygous BromoTag-Brd2 HEK293 cells. Scatterplot depicting
the effect of 46 (blue) and 52 (red) treatment on the proteome of
heterozygous BromoTag-Brd2 HEK293 cells treated with 1 μM of
compound for 2 h. Brd2 expression is highlighted for both treatment
conditions. The data plotted is log2 of the normalized fold change in
abundance against −log10 of the p value per protein identified from
TMT mass spectrometry analysis produced from three independent
experiments.
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and the reaction was left to stir at −78 °C for 1 h. Alkyl iodide (0.41
mmol) was then added, and the reaction was stirred for a further 10
min at −78 °C before warming to r.t. and leaving to stir for 16 h. The
mixture was then concentrated in vacuo and purified by HPLC using a
linear gradient of 30−70% MeCN in 0.1% formic acid in water over
12 min to afford alkylated JQ1-OMe derivatives.
4.1.6. General Procedure E. (2S,3S) Diastereomers (1 equiv) and
NaOMe (10 equiv) were dissolved in MeOH (60 mL/mmol) in a
closed, N2-purged, microwave vial and heated to 120 °C under
microwave irradiation for 40 min. The reaction was stirred at 60 °C
before acidifying with a few drops of AcOH. The reaction was then
cooled to r.t. and concentrated in vacuo. The residues were purified by
HPLC using a linear gradient of 30−70% MeCN in 0.1% formic acid
in water over 12 min.
4.1.7. General Procedure F. ET-JQ1-OH (45, synthesized
according to the literature21) (1 equiv) was dissolved in DCM (9
mL/mmol) under an atmosphere of N2. Thionyl chloride (15 equiv)
was then added, the reaction was left to stir at r.t. for 3 h, and
conversion to acid chloride was monitored by LCMS in MeOH
[monitor through the mass of methyl ester (∼443)]. The mixture was
evaporated to dryness to afford the acid chloride intermediate
quantitatively. Alcohols (1 equiv) were dissolved in DCM (9 mL/
mmol) and added to the acid chloride. This was left to stir at r.t. for





(MZP-15) (14). Following general procedure A, compound 14 was
obtained using acid 10 (synthesized according to the literature40)
without HOAt in DCM and purified by HPLC using a linear gradient
of 5−95% MeCN in 0.1% formic acid in water over 12 min to afford
14 as a mixture of two diastereomers. Yield: 16.5 mg (47%); 1H NMR
(400 MHz, CDCl3): δ 8.70 (s, 1H), 8.63−8.61 (m, 1H), 8.31−8.28
(m, 1H), 8.10−8.03 (m, 1H), 7.52−7.45 (m, 3H), 7.41−7.28 (m,
8H), 7.20−7.16 (m, 1H), 6.86−6.84 (m, 1H), 4.87−4.81 (m, 1H),
4.71−4.63 (m, 2H), 4.57−4.48 (m, 2H), 4.41−4.28 (m, 2H), 4.22−
4.06 (m, 3H), 3.78 (s, 3H), 2.57−2.54 (m, 3H), 2.51−2.49 (m, 3H),
2.46−2.35 (m, 1H), 2.27−2.20 (m, 1H), 1.01−0.99 ppm (m, 9H);
13C NMR (101 MHz, CDCl3): δ 171.7, 171.5, 171.3, 171.1, 171.04,
171.01, 170.9, 170.7, 166.6, 166.4, 158.3, 156.74, 156.70, 150.6, 150.3,
148.3, 138.7, 138.6, 137.2, 137.1, 137.0, 131.1, 131.0, 130.62, 130.55,
130.4, 130.3, 129.51, 129.47, 129.2, 128.7, 128.6, 128.2, 128.1, 126.2,
124.95, 124.91, 120.3, 118.2, 118.1, 116.0, 71.7, 71.2, 70.9, 70.8, 70.6,
70.5, 70.4, 70.3, 70.22, 70.15, 59.2, 59.1, 57.5, 57.3, 56.9, 56.0, 53.6,
53.5, 43.2, 40.0, 39.9, 38.1, 38.0, 36.9, 36.7, 35.8, 35.6, 26.6, 16.0,







carboxamide (DAT487) (15). Following general procedure A,
compound 15 was obtained using acid 11 (synthesized according to
the literature20) in DMF and purified by HPLC using a linear gradient
of 5−95% MeCN in 0.1% ammonia in water over 12 min to afford 15
as a mixture of two diastereomers. Yield: 8.3 mg (23%); 1H NMR
(400 MHz, MeOD): δ 8.86 (d, J = 1.3 Hz, 1H), 7.72−7.67 (m, 1H),
7.56 (d, J = 8.5 Hz, 2H), 7.46−7.34 (m, 7H), 6.93−6.91 (m, 1H),
4.79−4.32 (m, 5H), 4.29−4.25 (m, 1H), 4.11−4.02 (m, 2H), 3.90−
3.85 (m, 1H), 3.82−3.77 (m, 4H), 3.74−3.40 (m, 13H), 3.30−3.14
(m, 1H), 2.59−2.58 (m, 3H), 2.47−2.46 (m, 3H), 2.27−2.17 (m,
2H), 2.11−2.03 (m, 1H), 1.75−1.63 (m, 1H), 1.07−1.01 ppm (m,
12H); 13C NMR (101 MHz, MeOD): δ 175.9, 174.42, 174.39, 172.1,
171.6, 168.8, 168.7, 159.9, 157.3, 152.8, 152.6, 149.0, 140.3, 140.2,
138.6, 138.14, 138.11, 133.4, 132.1, 131.5, 131.3, 130.3, 129.6, 129.0,
128.9, 127.5, 126.8, 119.2, 116.8, 72.3, 72.2, 71.75, 71.67, 71.5, 71.4,
71.0, 70.5, 70.4, 60.8, 58.5, 58.4, 58.1, 56.4, 49.84, 49.76, 43.8, 43.7,
40.4, 39.0, 37.2, 37.1, 26.99, 26.96, 24.53, 24.46, 15.9, 11.7, 11.6;
Figure 10. Plasma stability and in vivo PK studies of AGB1 (46) in mice. (A) Percentage of 46 remaining after 0, 5, 15, 30, 45, and 60 min in
mouse plasma at 37 °C, normalized to 0 min time point, with two independent repeats per time point. (B) Male C57BL/6 mice were treated with a
single 5 mg/kg dose of 46 by either IV (black dots) or SC (hollow squares) injection, and the blood plasma concentration of 46 was measured at
seven time points. Data is mean (±S.D.) from three independent repeats at each time point. The red dashed line indicates the DC50, 6h of 46 for
degrading BromoTag-Brd2.
Table 4. PK Study of AGB1 in Mice with IV Dosing Compared to MZ1
IV (5 mg/kg)
compound CL (mL/min/kg) Vss (L/kg) T1/2 (h) AUClast (μM·h) AUCinf (μM·h) MRTinf (h)
AGB1 (46) 47.2 1.10 1.49 1.71 1.72 0.390
MZ1 (1)a 19.7 0.38 1.04 4.51 0.340
aValues obtained from ref 38.













(μ; M·h) F (%)
AGB1
(46)
0.500 0.700 1.65 2.33 2.40 140
MZ1 (1)a 0.500 2.07 2.95 3.76 83
aValues obtained from ref 38.
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carboxamide (DAT488) (16). Following general procedure A,
compound 16 was obtained using acid 12 (synthesized according to
the literature20) in DMF and purified by HPLC using a linear gradient
of 5−95% MeCN in 0.1% ammonia in water over 12 min to afford 16
as a mixture of two diastereomers. Yield: 13.8 mg (28%); 1H NMR
(400 MHz, MeOD): δ 8.87−8.86 (m, 1H), 7.49−7.34 (m, 9H),
7.31−7.29 (m, 1H), 7.16−7.11 (m, 1H), 4.71−4.69 (m, 1H), 4.62−
4.56 (m, 1H), 4.55−4.46 (m, 2H), 4.38−4.32 (m, 1H), 4.25−4.21
(m, 1H), 4.09−4.00 (m, 2H), 3.97−3.96 (m, 3H), 3.90−3.72 (m,
3H), 3.71−3.59 (m, 11H), 3.53−3.42 (m, 2H), 2.66−2.64 (m, 3H),
2.47−2.45 (m, 3H), 2.25−2.18 (m, 1H), 2.11−2.04 (m, 1H), 1.36−
1.32 (m, 3H), 1.05−1.02 ppm (m, 9H); 13C NMR (101 MHz,
MeOD): δ 177.4, 174.39, 174.36, 172.1, 171.7, 171.6, 168.1, 168.0,
163.6, 156.8, 152.9, 152.8, 149.0, 140.3, 140.2, 138.9, 137.9, 135.8,
134.34, 134.32, 133.4, 132.4, 131.5, 130.4, 129.4, 128.9, 122.5, 115.2,
110.6, 72.2, 71.7, 71.6, 71.4, 71.1, 71.0, 70.7, 60.8, 60.7, 58.1, 56.7,
43.9, 43.7, 40.5, 38.9, 37.1, 27.0, 20.0, 16.1, 16.0, 15.9, 11.9; LCMS
m/z: calcd for C51H64ClN9O9S [M + 2H]





carboxamide (DAT489) (17). Following general procedure A,
compound 17 was obtained using acid 13 (synthesized according to
the literature20) in DMF and purified by HPLC using a linear gradient
of 5−95% MeCN in 0.1% ammonia in water over 12 min to afford 17
as a mixture of two diastereomers. Yield: 4.8 mg (20%); 1H NMR
(400 MHz, MeOD): δ 8.87−8.86 (m, 1H), 7.54−7.50 (m, 2H),
7.46−7.37 (m, 7H), 7.26 (d, J = 2.5 Hz, 1H), 7.15−7.12 (m, 1H),
4.74−4.70 (m, 1H), 4.69−4.51 (m, 2H), 4.50−4.46 (m, 1H), 4.42−
4.32 (m, 1H), 4.29−4.25 (m, 1H), 4.11−4.02 (m, 2H), 3.96 (s, 3H),
3.89−3.78 (m, 2H), 3.74−3.39 (m, 13H), 3.29−3.14 (m, 1H), 2.63−
2.62 (m, 3H), 2.47−2.46 (m, 3H), 2.28−2.18 (m, 2H), 2.11−2.02
(m, 1H), 1.75−1.62 (m, 1H), 1.06−1.01 ppm (m, 12H); 13C NMR
(101 MHz, MeOD): δ 176.0, 174.42, 174.39, 172.1, 171.6, 169.3,
169.2, 163.71, 163.69, 157.27, 157.26, 152.8, 152.6, 149.0, 140.3,
140.2, 139.1, 138.0, 138.0, 136.0, 134.30, 134.28, 133.4, 132.3, 131.5,
130.3, 129.5, 129.02, 128.95, 122.6, 115.1, 110.6, 72.4, 72.2, 71.75,
71.68, 71.50, 71.48, 71.4, 71.09, 71.06, 70.5, 70.4, 60.80, 60.78, 58.4,
58.3, 58.14, 58.10, 56.7, 49.8, 49.7, 43.8, 43.7, 40.4, 39.0, 37.2, 37.1,
27.00, 26.96, 24.5, 24.4, 15.9, 11.9, 11.7, 11.6; LCMS m/z: calcd for
C52H66ClN9O9S [M + 2H]





amide (ME-MZ1) (18). Following general procedure B, compound 18
was obtained using azide 9 (synthesized according to the literature14)
and alkylated JQ1 acid 32 to afford 18 as a mixture of two
diastereomers. Yield: 1.6 mg (19%); 1H NMR (400 MHz, CDCl3): δ
8.67 (s, 1H), 8.07 (t, J = 5.4 Hz, 1H), 7.89 (t, J = 5.1 Hz, 1H), 7.68 (t,
J = 6.0 Hz, 1H), 7.46−7.24 (m, 9H), 4.85−4.79 (m, 1H), 4.77−4.63
(m, 1H), 4.63−4.47 (m, 2H), 4.42−4.36 (m, 1H), 4.31−4.23 (m,
2H), 4.18−4.01 (m, 3H), 3.96−3.85 (m, 1H), 3.81−3.36 (m, 16H),
2.65−2.60 (m, 3H), 2.51 (s, 3H), 2.50−2.37 (m, 4H), 2.26−2.11 (m,
1H), 1.73−1.64 (m, 3H), 1.42−1.35 (m, 3H), 1.01−0.94 ppm (m,
9H); 13C NMR (101 MHz, CDCl3): δ 175.2, 171.51, 171.49, 171.2,
170.7, 170.5, 163.3, 163.2, 158.2, 155.14, 155.09, 150.4, 149.8, 148.6,
138.6, 138.5, 136.9, 136.8, 136.69, 136.65, 131.9, 131.25, 131.15,
130.8, 130.2, 129.6, 129.5, 128.9, 128.8, 128.2, 128.0, 71.6, 71.4, 70.9,
70.6, 70.5, 70.4, 70.3, 70.25, 70.20, 70.1, 60.5, 60.1, 59.1, 58.9, 57.5,
57.3, 56.8, 56.7, 43.3, 43.2, 42.7, 42.6, 39.9, 36.4, 36.3, 35.9, 35.8,
26.6, 26.5, 16.4, 16.2, 16.1, 14.6, 13.3, 11.91, 11.87; HRMS m/z: calcd
for C50H63ClN9O8S2 [M + H]





amide (ET-MZ1) (19). Following general procedure B, compound 19
was obtained using azide 9 (synthesized according to the literature14)
and alkylated JQ1 acid 33 to afford 19 as a mixture of two
diastereomers. Yield: 5.3 mg (47%); 1H NMR (500 MHz, CDCl3): δ
8.68−8.66 (m, 1H), 8.10−8.05 (m, 1H), 7.83−7.79 (m, 1H), 7.69−
7.65 (m, 1H), 7.40−7.26 (m, 8H), 7.21−7.16 (m, 2H), 4.87−4.76
(m, 2H), 4.68−4.49 (m, 2H), 4.49−4.36 (m, 1H), 4.28−4.24 (m,
1H), 4.18−4.00 (m, 3H), 3.81−3.74 (m, 1H), 3.74−3.34 (m, 13H),
2.65−2.62 (m, 3H), 2.53−2.51 (m, 3H), 2.49−2.44 (m, 1H), 2.41−
2.38 (m, 3H), 2.36−2.30 (m, 1H), 2.25−2.11 (m, 1H), 1.97−1.89
(m, 1H), 1.71−1.59 (m, 4H), 1.03−0.93 ppm (m, 12H); 13C NMR
(126 MHz, CDCl3): δ 174.2, 173.9, 171.7, 171.6, 171.2, 170.4, 170.3,
163.8, 163.2, 155.3, 155.1, 150.3, 149.9, 149.8, 148.6, 138.7, 138.6,
136.95, 136.91, 136.8, 136.7, 132.1, 131.94, 131.90, 131.3, 131.1,
131.0, 130.9, 130.8, 130.7, 130.2, 130.1, 129.9, 129.6, 129.5, 129.0,
128.8, 128.3, 127.6, 71.3, 71.2, 71.1, 70.9, 70.8, 70.7, 70.50, 70.47,
70.3, 70.18, 70.15, 59.8, 59.4, 59.2, 58.9, 57.63, 57.59, 56.8, 50.3, 50.1,
43.3, 43.0, 39.9, 39.8, 36.9, 36.4, 35.90, 35.85, 26.6, 23.7, 23.2, 16.21,
16.19, 14.6, 14.5, 13.2, 12.0; HRMS m/z: calcd for C51H65ClN9O8S2





2-carboxamide (ME-ARV-771) (20). Following general procedure B,
compound 20 was obtained using azide 42 (synthesized according to
the literature30) and alkylated JQ1 acid 32 to afford 20 as a mixture of
two diastereomers. Yield: 5.2 mg (31%); 1H NMR (500 MHz,
CDCl3): δ 8.71−8.69 (m, 1H), 7.66−7.61 (m, 1H), 7.57−7.21 (m,
9H), 5.14−4.98 (m, 1H), 4.86−4.80 (m, 1H), 4.65−4.47 (m, 2H),
4.34−4.24 (m, 1H), 4.21−3.77 (m, 4H), 3.75−3.33 (m, 11H), 2.69−
2.63 (m, 3H), 2.53−2.50 (m, 3H), 2.41 (s, 3H), 2.38−2.28 (m, 1H),
2.23−2.10 (m, 1H), 1.92−1.71 (m, 2H), 1.67 (d, J = 3.1 Hz, 3H),
1.48 (d, J = 21.4 Hz, 3H), 1.43−1.35 (m, 3H), 1.10−1.05 ppm (m,
9H); 13C NMR (126 MHz, CDCl3): δ 175.3, 175.0, 171.5, 171.4,
170.8, 170.6, 170.42, 170.38, 164.1, 163.9, 155.0, 154.9, 150.5, 150.22,
150.16, 148.2, 143.9, 143.7, 137.3, 136.4, 136.1, 132.0, 131.8, 131.33,
131.26, 130.6, 130.5, 130.3, 129.6, 129.55, 129.48, 128.92, 128.88,
126.6, 70.4, 70.32, 70.29, 70.2, 69.6, 69.4, 69.2, 67.84, 67.77, 59.9,
59.8, 58.9, 58.8, 57.5, 57.3, 57.1, 57.0, 49.1, 48.9, 42.6, 42.3, 39.7,
39.5, 36.6, 36.5, 35.5, 35.3, 29.53, 29.46, 26.7, 22.4, 22.1, 16.5, 16.3,
16.1, 14.6, 13.3, 11.8, 11.7; HRMS m/z: calcd for C50H63ClN9O7S2





2-carboxamide (ET-ARV-771) (21). Following general procedure B,
compound 21 was obtained using azide 42 (synthesized according to
the literature30) and alkylated JQ1 acid 33 to afford 21 as a mixture of
two diastereomers. Yield: 3.4 mg (27%); 1H NMR (400 MHz,
CDCl3): δ 8.68 (s, 1H), 7.94−7.90 (m, 1H), 7.71−7.65 (m, 1H),
7.44−7.31 (m, 7H), 7.25−7.22 (m, 1H), 7.17−7.13 (m, 1H), 5.14−
4.87 (m, 1H), 4.75−4.58 (m, 1H), 4.53−4.44 (m, 1H), 4.09−3.98
(m, 1H), 3.94−3.87 (m, 2H), 3.80−3.31 (m, 11H), 2.67−2.61 (m,
2H), 2.54−2.49 (m, 3H), 2.41 (s, 2H), 2.37−2.14 (m, 2H), 1.98−
1.47 (m, 11H), 1.11−0.94 ppm (m, 12H); 13C NMR (101 MHz,
CDCl3): δ 174.04, 174.00, 172.3, 171.5, 170.59, 170.55, 170.32,
170.25, 163.6, 163.2, 162.4, 155.3, 155.1, 150.4, 144.0, 143.4, 137.1,
136.9, 136.6, 131.3, 131.2, 131.1, 130.64, 130.59, 130.5, 130.10,
130.07, 130.0, 129.6, 129.4, 128.84, 128.80, 128.7, 126.6, 126.5, 70.4,
70.30, 70.26, 70.2, 69.6, 69.4, 69.1, 68.1, 67.7, 59.6, 59.0, 58.8, 58.6,
57.4, 57.1, 57.0, 50.3, 50.2, 49.1, 48.8, 39.8, 39.4, 36.6, 35.7, 35.6,
29.8, 29.6, 29.5, 26.7, 23.9, 23.4, 22.5, 21.9, 16.2, 14.61, 14.56, 13.3,
12.00, 11.97, 11.91, 11.87; HRMS m/z: calcd for C51H65ClN9O7S2
[M + H]+, 1014.4131; found, 1014.4126.
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6-yl)propanoate (ME-OMZ1) (22). Following general procedure C,
compound 22 was obtained using alkylated JQ1 acid 32 and alcohol
41 (synthesized according to the literature30) to afford 22 as a
mixture of two diastereomers. Yield: 1.1 mg (17%); 1H NMR (400
MHz, CDCl3): δ 8.69−8.67 (m, 1H), 7.67−7.65 (m, 1H), 7.44−7.28
(m, 10H), 4.78−4.73 (m, 1H), 4.69−4.50 (m, 3H), 4.41−4.24 (m,
3H), 4.13−3.81 (m, 5H), 3.77−3.49 (m, 12H), 2.63 (d, J = 15.9 Hz,
3H), 2.59−2.50 (m, 4H), 2.42 (s, 3H), 1.73−1.66 (m, 3H), 1.58−
1.48 (m, 3H), 0.99−0.94 ppm (m, 9H); 13C NMR (101 MHz,
CDCl3): δ 175.4, 171.6, 170.9, 170.6, 170.5, 163.2, 154.5, 150.4,
149.8, 148.7, 142.1, 140.3, 138.4, 136.9, 136.6, 132.4, 131.7, 131.1,
131.0, 131.0, 130.0, 129.6, 128.9, 128.8, 128.3, 71.30, 71.28, 71.0,
70.93, 70.89, 70.7, 70.6, 70.5, 70.44, 70.36, 69.3, 64.1, 64.0, 61.8, 61.7,
60.2, 60.1, 58.7, 58.6, 57.3, 56.8, 56.7, 43.4, 42.7, 42.6, 36.1, 36.0,
35.2, 26.6, 16.2, 16.1, 15.4, 15.3, 14.60, 14.56, 13.3, 11.9; HRMS m/z:
calcd for C50H62ClN8O9S2 [M + H]





6-yl)butanoate (ET-OMZ1) (23). Following general procedure C,
compound 23 was obtained using alkylated JQ1 acid 33 and alcohol
41 (synthesized according to the literature30) to afford 23 as a
mixture of two diastereomers. Yield: 0.7 mg (10%); 1H NMR (500
MHz, CDCl3): δ 8.67 (s, 1H), 7.41−7.23 (m, 10H), 4.77 (t, J = 7.9
Hz, 1H), 4.60−4.31 (m, 6H), 4.24 (d, J = 10.9 Hz, 1H), 4.15−4.11
(m, 1H), 4.05−3.89 (m, 3H), 3.80−3.74 (m, 2H), 3.72−3.52 (m,
10H), 2.65 (s, 3H), 2.60−2.51 (m, 4H), 2.41 (s, 3H), 2.17−2.10 (m,
2H), 1.71−1.64 (m, 4H), 1.05−0.93 ppm (m, 12H); 13C NMR (126
MHz, CDCl3): δ 174.8, 174.1, 171.5, 171.1, 170.5, 163.2, 163.0,
154.6, 150.4, 149.9, 148.7, 141.2, 136.9, 136.7, 132.2, 131.8, 131.0,
130.7, 130.0, 129.7, 128.8, 128.4, 128.3, 71.32, 71.30, 70.98, 70.96,
70.91, 70.85, 70.8, 70.7, 70.6, 70.54, 70.51, 70.3, 69.3, 63.9, 63.8, 59.4,
58.5, 57.3, 56.8, 49.8, 49.7, 43.44, 43.41, 36.0, 35.1, 26.6, 23.4, 16.2,
14.6, 13.3, 11.9, 11.7, 16.1, 15.4, 15.3, 14.60, 14.56, 13.3, 11.9; HRMS







[4,3-a][1,4]diazepin-6-yl)propanoate (ME-OARV-771) (24). Follow-
ing general procedure C, compound 24 was obtained using alkylated
JQ1 acid 32 and alcohol 44 (synthesized according to the literature30)
to afford 24 as a mixture of two diastereomers. Yield: 1.8 mg (25%);
1H NMR (500 MHz, CDCl3): δ 8.68−8.66 (m, 1H), 7.51−7.44 (m,
1H), 7.42−7.28 (m, 8H), 7.23−7.16 (m, 1H), 5.52 (br s, 1H), 5.14−
5.06 (m, 1H), 4.81−4.71 (m, 1H), 4.70−4.51 (m, 2H), 4.43−4.31
(m, 2H), 4.27 (d, J = 10.5 Hz, 1H), 4.13−4.08 (m, 1H), 4.07−3.81
(m, 4H), 3.75−3.54 (m, 8H), 3.19 (br s, 1H), 2.66−2.62 (m, 3H),
2.59−2.52 (m, 4H), 2.42 (s, 3H), 2.17−2.08 (m, 1H), 1.96−1.85 (m,
2H), 1.69 (d, J = 4.8 Hz, 3H), 1.56−1.47 (m, 6H), 1.08−1.05 ppm
(m, 9H); 13C NMR (126 MHz, CDCl3): δ 175.4, 174.3, 171.8, 171.5,
170.3, 169.8, 169.7, 169.5, 163.1, 154.5, 150.3, 149.8, 148.7, 136.9,
136.7, 132.2, 131.8, 131.0, 130.7, 130.0, 129.7, 128.9, 128.8, 126.65,
126.60, 73.2, 72.2, 70.5, 70.4, 70.3, 69.3, 69.0, 68.9, 68.0, 67.9, 63.9,
61.9, 60.1, 59.6, 58.8, 58.5, 57.2, 56.8, 56.6, 53.6, 49.1, 49.0, 42.6,
35.6, 35.3, 33.5, 30.0, 26.7, 26.6, 22.4, 22.3, 16.2, 15.3, 14.60, 14.55,







[4,3-a][1,4]diazepin-6-yl)butanoate (ET-OARV-771) (25). Following
general procedure C, compound 24 was obtained using alkylated JQ1
acid 32 and alcohol 44 (synthesized according to the literature30) to
afford 24 as a mixture of two diastereomers. Yield: 1.7 mg (24%); 1H
NMR (500 MHz, CDCl3): δ 8.66 (s, 1H), 7.47−7.28 (m, 10H),
7.20−7.13 (m, 1H), 5.12−5.04 (m, 1H), 4.81−4.75 (m, 1H), 4.70−
4.52 (m, 2H), 4.49−4.31 (m, 2H), 4.28−4.22 (m, 1H), 4.18−4.11
(m, 1H), 4.07−3.94 (m, 2H), 3.91−3.81 (m, 2H), 3.80−3.64 (m,
3H), 3.63−3.54 (m, 5H), 3.07 (s, 1H), 2.67−2.65 (m, 3H), 2.59−
2.52 (m, 4H), 2.41 (s, 3H), 2.19−2.05 (m, 2H), 1.96−1.85 (m, 2H),
1.72−1.64 (m, 4H), 1.49−1.46 (m, 3H), 1.07−1.01 ppm (m, 12H);
13C NMR (126 MHz, CDCl3): δ 175.0, 174.9, 171.9, 171.8, 170.42,
170.38, 169.8, 169.7, 163.2, 154.6, 154.5, 150.3, 149.89, 149.85, 148.7,
143.42, 143.36, 136.92, 136.90, 136.71, 136.67, 131.8, 131.0, 130.1,
130.0, 129.7, 128.8, 126.6, 72.2, 70.32, 70.26, 70.2, 69.3, 69.0, 68.9,
68.0, 67.9, 63.8, 62.0, 59.4, 58.45, 58.40, 57.2, 56.8, 56.7, 49.8, 49.7,
49.0, 35.6, 35.4, 35.2, 35.1, 30.1, 26.7, 26.6, 23.43, 23.39, 22.4, 16.2,
14.6, 13.3, 12.0, 11.7; HRMS m/z: calcd for C51H64ClN8O8S2 [M +
H]+, 1015.3972; found, 1015.4032.
4.1.20. Methyl 2-(5-(4-chlorophenyl)-6,7-dimethyl-2-oxo-2,3-di-
hydro-1H-thieno[2,3-e][1,4]diazepin-3-yl)acetate (28). Fmoc-Asp-
(OMe)-OH (26) (1.92 g, 5.19 mmol) was dissolved in DCM (25
mL). Thionyl chloride (3.76 mL, 51.9 mmol) was added, and the
reaction was left to reflux for 2 h. The reaction mixture was then
concentrated in vacuo to yield the intermediate acid chloride. Acid
chloride (2.01 g, 5.19 mmol) was dissolved in chloroform (10 mL).
(2-Amino-4,5-dimethylthiophen-3-yl)(4-chlorophenyl)methanone
(27) (1.38 g, 5.19 mmol) was then added, and the flask was heated to
reflux and stirred for 1 h. The mixture was then cooled to r.t. before
TEA (2.89 mL, 20.76 mmol) was added. The flask was heated to
reflux for a further 16 h. The reaction mixture was then concentrated
in vacuo and redissolved in 1,2-DCE (50 mL) and acidified with
AcOH (3.5 mL). This was left to stir at 80 °C for 1 h. The mixture
was then evaporated to dryness before redissolving in DCM (50 mL)
and washing with 1.0 M HCl solution (40 mL). The aqueous phase
was extracted with DCM (3 × 50 mL), and the combined organic
layers were dried with MgSO4, filtered, and concentrated in vacuo.
The residue was purified by flash column chromatography (24 g silica
column) using a linear gradient from 0 to 80% EtOAc in heptane to
afford 28. Yield: 1.06 g (54%); 1H NMR (500 MHz, CDCl3): δ 7.43
(d, J = 8.6 Hz, 2H), 7.34 (d, J = 8.7 Hz, 2H), 4.26 (dd, J = 6.6, 7.4 Hz,
1H), 3.74 (s, 3H), 3.44 (dd, J = 7.5, 16.8 Hz, 1H), 3.17 (dd, J = 6.5,
16.8 Hz, 1H), 2.29 (s, 3H), 1.60 ppm (s, 3H); LCMS m/z: calcd for
C18H18ClN2O3S [M + H]
+, 377.1; found, 377.0.
4.1.21. Methyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno-
[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate [(±)-JQ1-
OMe] (29). Compound 28 (344 mg, 0.91 mmol) was dissolved in
THF (7 mL) and cooled to −78 °C before addition of a solution of
1.0 M KOtBu in THF (1.37 mL, 1.37 mmol) and stirred for 30 min.
Diethyl chlorophosphate (198 μL, 1.37 mmol) was then added, and
the reaction was warmed to −10 °C and stirred for 45 min. Acetyl
hydrazine (135 mg, 1.82 μmol) was then added, and the reaction was
left to stir at r.t. for 1 h. n-BuOH (7.8 mL) was then added before
heating to 90 °C for 1 h. The reaction was concentrated in vacuo, and
the residue was purified by flash column chromatography (40 g silica
column) using a linear gradient from 3 to 50% EtOAc in heptane to
remove the starting material and the column was flushed with 20%
MeOH in DCM. Some fractions were further purified by HPLC using
a linear gradient of 35−55% MeCN in 0.1% formic acid in water over
12 min to afford 29. Yield: 173 mg (46%); 1H NMR (400 MHz,
CDCl3): δ 7.41 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 4.62
(dd, J = 6.9, 6.9 Hz, 1H), 3.77 (s, 3H), 3.70−3.57 (m, 2H), 2.67 (s,
3H), 2.41 (s, 3H), 1.69 ppm (s, 3H); LCMS m/z: calcd for
C20H20ClN4O2S [M + H]
+, 415.1; found, 415.0.
4.1.22. (±)-Methyl (R)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-
6H-thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)propanoate
[(±)-(3S,2R)-ME-JQ1-OMe] (30a). Following general procedure D,
compound 30a was obtained using an alkylating agent, methyl iodide.
Yield 8.9 mg (7%). Following general procedure E, compound 30a
can also be obtained from epimerization of 30b. Isolated yield: 12 mg
(31%); 1H NMR (500 MHz, CDCl3): δ 7.34 (d, J = 8.7 Hz, 2H), 7.31
(d, J = 8.8 Hz, 2H), 4.25 (d, J = 10.7 Hz, 1H), 4.07 (qd, J = 6.9, 10.7
Hz, 1H), 3.83 (s, 3H), 2.67 (s, 3H), 2.42 (s, 3H), 1.69 (s, 3H), 1.51
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c01532
J. Med. Chem. 2021, 64, 15477−15502
15494
ppm (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 176.1,
163.2, 154.5, 149.8, 136.9, 136.7, 132.3, 131.1, 130.9, 130.7, 130.0,
128.8, 60.4, 51.9, 42.6, 15.4, 14.6, 13.2, 12.0; LCMS m/z: calcd for
C21H22ClN4O2S [M + H]
+, 429.1; found, 429.0.
4.1.23. (±)-Methyl (S)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-
6H-thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)propanoate
[(±)-(3S,2S)-ME-JQ1-OMe] (30b). Following general procedure D,
compound 30b was obtained using an alkylating agent, methyl iodide.
Yield 35.4 mg (29%); 1H NMR (500 MHz, CDCl3): δ 7.43 (d, J = 8.4
Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 4.31 (d, J = 9.8 Hz, 1H), 3.88 (qd,
J = 7.2, 9.7 Hz, 1H), 3.72 (s, 3H), 2.64 (s, 3H), 2.41 (s, 3H), 1.70 (s,
3H), 1.62 ppm (d, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ
176.1, 163.9, 155.5, 149.6, 136.95, 136.90, 132.7, 130.8, 130.4, 129.9,
128.8, 58.5, 52.1, 41.2, 15.4, 14.5, 13.2, 11.9; LCMS m/z: calcd for
C21H22ClN4O2S [M + H]
+, 429.1; found, 429.0.
4.1.24. (±)-Methyl (R)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-
6H-thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)butanoate
[(±)-(3S,2R)-ET-JQ1-OMe] (31a). Following general procedure D,
compound 31a was obtained using an alkylating agent, ethyl iodide.
Yield 20 mg (16%). Following general procedure E, compound 31a
can also be obtained from epimerization of 31b. Isolated yield: 11 mg
(37%); 1H NMR (500 MHz, CDCl3): δ 7.35−7.29 (m, 4H), 4.24 (d,
J = 10.9 Hz, 1H), 3.99 (dt, J = 3.7, 10.7 Hz, 1H), 3.84 (s, 3H), 2.66
(s, 3H), 2.41 (s, 3H), 2.23−2.13 (m, 1H), 1.73−1.63 (m, 4H), 1.02
ppm (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.5,
163.2, 154.6, 149.8, 136.9, 136.7, 132.3, 131.0, 130.9, 130.6, 129.9,
128.8, 59.5, 51.6, 49.8, 23.4, 14.6, 13.2, 12.0, 11.7; LCMS m/z: calcd
for C22H24ClN4O2S [M + H]
+, 443.1; found, 443.1.
4.1.25. (±)-Methyl (S)-2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-
6H-thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)butanoate
[(±)-(3S,2S)-ET-JQ1-OMe] (31b). Following general procedure B,
compound 31b was obtained using an alkylating agent, ethyl iodide.
Yield 29.2 mg (23%); 1H NMR (500 MHz, CDCl3): δ 7.42 (d, J = 8.4
Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 4.31 (d, J = 10.9 Hz, 1H), 3.83 (dt,
J = 3.6, 10.1 Hz, 1H), 3.73 (s, 3H), 2.64 (s, 3H), 2.41 (s, 3H), 2.37−
2.26 (m, 1H), 1.93−1.82 (m, 1H), 1.69 (s, 3H), 1.05 ppm (t, J = 7.5
Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.5, 163.9, 155.4, 149.6,
136.95, 136.90, 132.7, 130.8, 130.7, 130.3, 129.9, 128.8, 57.6, 51.9,
47.6, 23.4, 14.5, 13.2, 11.9, 11.2; LCMS m/z: calcd for
C22H24ClN4O2S [M + H]
+, 443.1; found, 443.1.
4.1.26. (±)-(R)-2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-
thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)propanoic
Acid [(±)-(3S,2R)-ME-JQ1-OH] (32). Compound 30a (8.2 mg, 19
μmol) was dissolved in THF (400 μL). LiOH (1 mg, 38 μmol) was
subsequently dissolved in water (100 μL) and added to the flask. The
flask was heated to 35 °C and stirred for 48 h. Water (25 μL) and 0.6
M LiOH solution (25 μL) were added at regular intervals (every 12
h) to assist with the conversion. The conversion of the ester to the
acid was monitored by liquid chromatography−mass spectrometry
(LC−MS). After 100% conversion, the solution was neutralized with
2.0 M HCl solution and freeze-dried to afford acid 32. The acid was
used as crude for the next step and the yield considered quantitative.
Yield: 7.9 mg, (quant.); 1H NMR (500 MHz, CDCl3): δ 7.34 (d, J =
8.8 Hz, 2H), 7.31 (d, J = 8.9 Hz, 2H), 4.25 (d, J = 10.6 Hz, 1H), 4.07
(m, 1H), 3.83 (s, 3H), 2.67 (s, 3H), 2.42 (s, 3H), 1.69 (s, 3H), 1.51
ppm (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 175.8,
164.8, 154.6, 150.3, 137.7, 135.7, 132.4, 131.6, 131.4, 130.9, 130.3,
129.0, 59.1, 41.5, 15.6, 14.6, 13.4, 11.8; LCMS m/z: calcd for
C20H20ClN4O2S [M + H]
+, 415.1; found, 415.1.
4.1.27. (±)-(R)-2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-
thieno[3,2-f ][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)butanoic Acid
[(±)-(3S,2R)-ET-JQ1-OH] (33). Compound 31a (35.2 mg, 80 μmol)
was dissolved in THF (1.2 mL). LiOH (4.8 mg, 200 μmol) was
subsequently dissolved in water (300 μL) and added to the flask. The
flask was heated to 40 °C and stirred for 6 days. Water (50 μL) and
0.65 M LiOH solution (50 μL) were added at regular intervals (every
12 h) to assist with the conversion. The conversion of the ester to the
acid was monitored by LC−MS. After 100% conversion, the solution
was neutralized with 2.0 M HCl solution and freeze-dried to afford
acid 33. The acid was used as crude for the next step and the yield
considered quantitative. Yield: 34.3 mg, (quant.); 1H NMR (500
MHz, CDCl3): δ 7.41 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.7 Hz, 2H),
4.24 (d, J = 6.5 Hz, 1H), 3.75−3.70 (m, 1H), 2.69 (s, 3H), 2.43 (s,
3H), 2.03−1.95 (m, 2H), 1.71 (s, 3H), 1.10 ppm (t, J = 7.4 Hz, 3H);
13C NMR (126 MHz, CDCl3): δ 175.2, 164.6, 154.9, 150.1, 137.5,
136.1, 132.5, 131.5, 131.2, 130.2, 130.1, 129.0, 58.2, 48.6, 23.8, 14.6,







butanoate (AGB1) (46). Following general procedure F, compound
46 was obtained using alcohol 41 (synthesized according to the
literature30) and purified by reversed-phase flash column chromatog-
raphy (15.5 g of C18 gold column) using a linear gradient from 5 to
100% MeCN in 0.1% formic acid in water over 12 min to afford
AGB1 (46). Yield: 29 mg (30%); 1H NMR (500 MHz, CDCl3): δ
8.67 (s, 1H), 7.42 (t, J = 5.9 Hz, 1H), 7.36−7.28 (m, 9H), 4.74 (t, J =
7.9 Hz, 1H), 4.56−4.49 (m, 3H), 4.44−4.30 (m, 3H), 4.23 (d, J =
10.9 Hz, 1H), 4.06 (d, J = 11.3 Hz, 1H), 4.01 (d, J = 15.7 Hz, 1H),
3.98−3.92 (m, 2H), 3.81−3.72 (m, 2H), 3.69−3.59 (m, 10H), 2.65
(s, 3H), 2.53−2.45 (m, 4H), 2.41 (s, 3H), 2.18−2.09 (m, 2H), 1.73−
1.62 (m, 4H), 1.01 (t, J = 7.4 Hz, 3H), 0.95 ppm (s, 9H); 13C NMR
(126 MHz, CDCl3): δ 174.8, 171.4, 171.1, 170.5, 163.2, 162.9, 154.5,
150.5, 149.9, 148.5, 138.4, 136.9, 136.6, 132.1, 131.8, 131.1, 131.0,
130.9, 130.7, 130.0, 129.6, 128.8, 128.2, 71.3, 70.9, 70.8, 70.6, 70.5,
70.2, 69.3, 63.8, 59.3, 58.7, 57.2, 56.8, 49.7, 43.3, 36.2, 35.3, 26.5,
23.3, 16.1, 14.5, 13.2, 11.9, 11.7; HRMS m/z: calcd for
C51H64ClN8O9S2 [M + H]





[4,3-a][1,4]diazepin-6-yl)butanoate (AGB2) (47). Following general
procedure F, compound 47 was obtained using alcohol 44
(synthesized according to the literature30) and purified by HPLC
using a linear gradient from 5 to 95% MeCN in 0.1% formic acid over
12 min in water to afford AGB2 (47). Yield: 1.2 mg (10%); 1H NMR
(500 MHz, CDCl3): δ 8.66 (s, 1H), 7.47 (d, J = 7.3 Hz, 1H), 7.39 (d,
J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H),
7.29 (d, J = 8.8 Hz, 2H), 7.20 (d, J = 8.6 Hz, 1H), 5.08 (dq, J = 7.2,
7.2 Hz, 1H), 4.78 (t, J = 7.9 Hz, 1H), 4.56 (d, J = 8.6 Hz, 1H), 4.55−
4.51 (m, 1H), 4.49−4.43 (m, 1H), 4.35−4.30 (m, 1H), 4.25 (d, J =
10.8 Hz, 1H), 4.12 (d, J = 11.3 Hz, 1H), 4.00−3.93 (m, 2H), 3.87 (d,
J = 15.4 Hz, 1H), 3.80−3.75 (m, 1H), 3.75−3.69 (m, 1H), 3.64−3.58
(m, 5H), 2.65 (s, 3H), 2.58−2.52 (m, 4H), 2.41 (s, 3H), 2.20−2.12
(m, 1H), 2.09 (dd, J = 8.3, 13.6 Hz, 1H), 1.93−1.86 (m, 2H), 1.73−
1.63 (m, 4H), 1.47 (d, J = 6.9 Hz, 3H), 1.06 (s, 9H), 1.02 ppm (t, J =
7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 174.9, 171.8, 170.4,
169.8, 163.2, 154.6, 150.3, 149.9, 148.7, 143.4, 136.9, 136.6, 131.02,
130.99, 130.0, 129.7, 128.8, 126.6, 70.3, 70.2, 69.0, 68.9, 68.0, 63.8,
59.4, 58.5, 57.1, 56.8, 49.8, 49.0, 35.6, 35.2, 30.0, 29.8, 26.7, 23.4,
22.4, 16.2, 14.6, 13.3, 11.9, 11.7; HRMS m/z: calcd for
C51H64ClN8O8S2 [M + H]





amide (AGB3) (48). Azide 9 (synthesized according to the
literature14) (30 mg, 46 μmol) was dissolved in MeOH (2 mL). A
catalytic amount of 10 wt % Pd/C was added, and the reaction was
stirred under an atmosphere of hydrogen for 3 h. The reaction
mixture was then filtered through PTFE syringe filters and evaporated
to dryness to obtain the desired amine quantitative yields. The
resulting amine (7.4 mg, 12 μmol) was dissolved in DMF (96 μL) and
added to a solution of ET-JQ1-OH (45, synthesized according to the
literature21) (5 mg, 12 μmol), COMU (5.1 mg, 12 μmol) and DIPEA
(4.18 μL, 12 μmol) in DMF (96 μL) and stirred at r.t. for 2 h. The
mixtures were then concentrated in vacuo, and the residues were
purified by HPLC using a linear gradient of 5−95% MeCN in 0.1%
formic acid in water over 12 min to afford AGB3 (48). Yield: 2.2 mg
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c01532
J. Med. Chem. 2021, 64, 15477−15502
15495
(18%); 1H NMR (400 MHz, CDCl3): δ 8.68 (s, 1H), 8.18 (t, J = 5.5
Hz, 1H), 7.36 (d, J = 8.3 Hz, 2H), 7.31−7.24 (m, 5H), 7.17−7.12 (m,
3H), 4.99 (d, J = 4.9 Hz, 1H), 4.85 (t, J = 8.2 Hz, 1H), 4.80 (d, J = 9.7
Hz, 1H), 4.51 (br s, 1H), 4.46 (dd, J = 7.2, 15.8 Hz, 1H), 4.26 (d, J =
10.5 Hz, 1H), 4.19−4.11 (m, 2H), 4.09 (d, J = 15.9 Hz, 1H), 3.83−
3.63 (m, 15H), 3.50−3.42 (m, 1H), 2.64 (s, 3H), 2.53 (s, 3H), 2.39
(s, 3H), 2.34−2.27 (m, 1H), 2.16 (dd, J = 7.5, 13.5 Hz, 1H), 1.96−
1.89 (m, 1H), 1.64−1.56 (m, 4H), 1.03−0.96 ppm (m, 12H); 13C
NMR (101 MHz, CDCl3): δ 173.8, 171.7, 171.6, 170.3, 163.9, 155.0,
150.3, 149.9, 148.5, 138.6, 136.9, 136.7, 132.0, 131.9, 131.31, 131.28,
130.9, 130.6, 130.1, 129.4, 129.0, 127.5, 71.3, 71.1, 70.75, 70.69, 70.4,
70.3, 59.8, 59.4, 57.7, 56.7, 50.3, 42.9, 39.8, 36.9, 36.0, 26.6, 23.1,
16.2, 14.6, 13.3, 12.0, 11.9; HRMS m/z: calcd for C51H65ClN9O8S2




mide (50). Acid 37 (synthesized according to the literature30) (161
mg, 0.36 mmol), COMU (154 mg, 0.36 mmol), and DIPEA (334 μL,
1.92 mmol) were dissolved in DMF (1.92 mL) and stirred at r.t. for
10 min. Amine 49 (synthesized according to the literature14) (112
mg, 0.24 mmol) was added, and the reaction was left to stir at r.t. for 2
h. The mixture was then purified by reversed-phase flash column
chromatography (2 × 15.5 g C18 column) using a linear gradient
from 5 to 100% MeCN in 0.1% formic acid in water over 10 min with
a 3 min plateau to afford 50. Yield: 103 mg (50%); 1H NMR (500
MHz, CDCl3): δ 8.65 (s, 1H), 7.69−7.65 (m, 4H), 7.57 (t, J = 6.1 Hz,
1H), 7.43−7.31 (m, 10H), 7.20 (d, J = 9.1 Hz, 1H), 5.52 (d, J = 9.8
Hz, 1H), 4.71 (d, J = 9.0 Hz, 1H), 4.60 (dd, J = 7.0, 14.9 Hz, 1H),
4.52 (d, J = 9.1 Hz, 1H), 4.49−4.43 (m, 1H), 4.29 (dd, J = 5.1, 14.9
Hz, 1H), 4.01 (d, J = 15.6 Hz, 1H), 3.98−3.91 (m, 2H), 3.82−3.77
(m, 3H), 3.70−3.59 (m, 8H), 3.57 (t, J = 5.4 Hz, 2H), 2.50 (s, 3H),
2.34 (d, J = 14.0 Hz, 1H), 2.19−2.10 (m, 1H), 1.04 (s, 9H), 0.93 ppm
(s, 9H); 13C NMR (126 MHz, CDCl3): 172.7, 171.9, 169.9, 150.4,
148.7, 137.5, 135.7, 133.8, 131.6, 131.3, 129.7, 128.3, 127.7, 72.6,
71.3, 71.2, 70.9, 70.8, 70.54, 70.51, 63.5, 60.0, 58.7, 56.6, 43.6, 35.2,
35.1, 30.4, 26.9, 26.4, 19.3, 16.1; LCMS m/z: calcd for
C46H63N4O8SSi [M + H]
+, 859.4; found, 859.3.
4.1.32. (2S,4S)-1-((S)-2-(tert-Butyl)-14-hydroxy-4-oxo-6,9,12-tri-
oxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-
benzyl)pyrrolidine-2-carboxamide (51). To a solution of compound
50 (51 mg, 59 μmol) in THF (11.9 mL) was added a 1.0 M solution
of TBAF in THF (178 μL, 178 μmol). This was left to stir for 6 h.
The mixture was then concentrated in vacuo, and the residue was
purified by reversed-phase flash column chromatography (15.5 g C18
column) using a linear gradient from 5 to 100% MeCN in 0.1%
formic acid in water over 10 min to afford alcohol 51. Yield: 36.6 mg
(quant.); 1H NMR (500 MHz, CDCl3): δ 8.66 (s, 1H), 8.01 (t, J =
5.9 Hz, 1H), 7.38−7.32 (m, 4H), 7.29 (d, J = 9.4 Hz, 1H), 4.67 (d, J
= 8.7 Hz, 1H), 4.64−4.58 (m, 2H), 4.44 (t, J = 4.3 Hz, 1H), 4.30 (dd,
J = 5.1, 15.0 Hz, 1H), 4.04 (d, J = 15.6 Hz, 1H), 3.97 (d, J = 15.3 Hz,
1H), 3.89 (dd, J = 4.2, 10.9 Hz, 1H), 3.84 (d, J = 10.7 Hz, 1H), 3.71−
3.52 (m, 12H), 3.51−3.44 (m, 1H), 2.50 (s, 3H), 2.26 (d, J = 14.3
Hz, 1H), 2.23−2.15 (m, 1H), 0.96 ppm (s, 9H); 172.8, 171.8, 169.8,
150.4, 148.6, 137.7, 131.7, 131.2, 129.6, 128.2, 72.7, 71.2, 71.1, 70.9,
70.5, 70.35, 70.29, 61.7, 60.1, 58.8, 56.5, 43.6, 35.7, 35.5, 26.4, 16.1;
LCMS m/z: calcd for C30H45N4O8S [M + H]





butanoate (cis-AGB1) (52). Following general procedure F,
compound 52 was obtained using alcohol 51 and purified by
HPLC using a linear gradient from 5 to 95% MeCN in 0.1% formic
acid in water over 12 min to afford cis-AGB1 (52). Yield: 8.4 mg
(51%); 1H NMR (500 MHz, CDCl3): δ 8.67 (s, 1H), 7.63 (t, J = 5.8
Hz, 1H), 7.38−7.27 (m, 8H), 7.18 (d, J = 9.3 Hz, 1H), 5.54 (d, J =
10.1 Hz, 1H), 4.75 (d, J = 9.1 Hz, 1H), 4.61 (dd, J = 7.0, 14.9 Hz,
1H), 4.54 (d, J = 9.2 Hz, 1H), 4.49−4.33 (m, 3H), 4.30 (dd, J = 5.3,
15.0 Hz, 1H), 4.24 (d, J = 10.9 Hz, 1H), 4.01 (d, J = 15.8 Hz, 1H),
3.99−3.91 (m, 3H), 3.81 (d, J = 11.1 Hz, 1H), 3.79−3.75 (m, 2H),
3.70−3.62 (m, 8H), 2.65 (s, 3H), 2.51 (s, 3H), 2.41 (s, 3H), 2.34 (d,
J = 14.3 Hz, 1H), 2.21−2.13 (m, 2H), 1.72−1.64 (m, 4H), 1.02 (t, J =
7.5, 3H), 0.95 ppm (s, 9H); 13C NMR (126 MHz, CDCl3): δ 174.9,
172.9, 171.7, 169.9, 163.2, 154.5, 150.5, 149.9, 148.6, 137.6, 136.8,
136.5, 132.1, 131.6, 131.2, 131.0, 130.9, 130.5, 130.0, 129.7, 128.8,
128.3, 71.3, 71.2, 70.84, 70.81, 70.5, 69.3, 63.8, 60.0, 59.3, 58.7, 56.5,
49.8, 43.6, 35.30, 35.26, 26.4, 23.3, 16.2, 14.6, 13.3, 12.0, 11.7; HRMS
m/z: calcd for C51H64ClN8O9S2 [M + H]
+, 1031.3921; found,
1031.3987.
4.2. Biology. 4.2.1. Cell Culture. The HEK293 human embryonic
kidney adherent cell line (ATCC, Manassas, VA, USA) was cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine
serum (FBS) (Thermo Fisher, Waltham, MA, USA) and 1% (v/v)
penicillin/streptomycin (pen/strep) (#15140122, Thermo Fisher,
Waltham, MA, USA) at 37 °C, 5% CO2, and 95% humidity. 22RV1; a
human prostate carcinoma epithelial adherent cell line (ATCC,
Manassas, VA, USA) was cultured in RPMI-1640 (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% (v/v) FBS (Thermo
Fisher, Waltham, MA, USA) and 1% (v/v) penicillin/streptomycin
(pen/strep) (#15140122, Thermo Fisher, Waltham, MA, USA) at 37
°C, 5% CO2, and 95% humidity. The MV-4-11 human acute
monocytic leukemia suspension cell line (ATCC, Manassas, VA,
USA) was cultured in IMDM (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% (v/v) FBS (Thermo Fisher, Waltham, MA,
USA) and 1% (v/v) penicillin/streptomycin (pen/strep)
(#15140122, Thermo Fisher, Waltham, MA, USA) at 37 °C, 5%
CO2, and 95% humidity.
4.2.2. CRISPR BromoTag-Brd2 Knock-In Cell Line Generation.
HEK293 cells were maintained in DMEM (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% (v/v) FBS (Thermo Fisher, Waltham,
MA, USA) and 1% (v/v) penicillin/streptomycin (pen/strep)
(#15140122, Thermo Fisher, Waltham, MA, USA) at 37 °C, 5%
CO2, and 95% humidity. HEK293 cells (50,000) were plated into
individual wells of a six-well plate in 1 mL of DMEM (Invitrogen,
Carlsbad, CA, USA) for 24 h, leading up to the initiation of the
experiment. HEK293 cells were transfected using a Fugene HD
transfection reagent (Madison, Wisconsin, United States) or lipofect-
amine 2000 (Madison, Wisconsin, United States) simultaneously with
three custom vectors including a px335 vector (Addgene) containing
a U6-snRNA & Cas9D10A expression cassette, a pBABED vector
(MRC PPU, Dundee University) harboring another U6-sgRNA and
puromycin expression cassette, and finally a pcDNA5 vector
containing an eGFP-P2A-BromoTag-Brd2 donor knock-in sequence.
DNA fragment encoding for the selected guide RNA sequences
(BRD2-KI-1-s: AGGGCAGCGCCGGTTCCTTGCGG; BRD2-KI-2-
as: TCAGCCGCGGAAAGTCCGGGTGG) was cloned into plasmid
pX335 and a custom-made pBABE-Puromycin vector anchoring a
pU6 promoter, respectively, to provide the source of guide RNAs.
The donor DNA was designed by having a DNA sequence 500 bp
upstream and 500 bp downstream of the designated tag insertion site
of BRD2 (Entrez GeneID: 6046) forming a pair of homology arm
flanking DNA sequence encoding for GFP-P2A-BromoTag. The
donor DNA was obtained in the format of plasmid DNA by gene
synthesis service from GeneART. To increase the relative population
of cells undergoing homologous recombination, this transfection was
performed in the presence of 0.1 μM of the DNA ligase IV inhibitor
SCR7. The following day, cells were washed before applying fresh
DMEM containing 0.1 μM of SCR7 and 2 μg/mL of puromycin. This
was repeated the following day as cells were washed before applying
fresh DMEM containing 0.1 μM of SCR7 and 2 μg/mL of puromycin.
The following day, the cells were washed for the third time, and fresh
media without both SCR7 and puromycin was applied to allow for
recovery. The following day, HEK293 cells were washed and then
cultured with fresh DMEM containing 2.5 μg/mL of puromycin and
0.1 μM of SCR7. This process was continued for a further 2 days. The
cells were then washed with PBS before recovery in DMEM was
performed for a further 20 days. The cells were subsequently prepared
for FACS sorting.
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4.2.3. FACS of GFP-Positive CRISPR Knock-In BromoTag-Brd2
HEK293 Cells. HEK293 cells that had undergone CRISPR lipofection
and selection in the previous stage were subsequently trypsinized
using trypsin−EDTA (0.05%) and phenol red (Thermo Fisher,
Waltham, MA, USA). Once in suspension, the trypsin−cell mixture
was neutralized with FBS (Thermo Fisher, Waltham, MA, USA).
Cells were pelleted at 1500 rpm for 5 min. The cell pellet produced
was subsequently resuspended in DMEM supplemented with 1% FBS
at a concentration of 5 × 106 cells per mL. Wild-type HEK293 cells
were used as a baseline control for GFP expression. Single-cell clones
were generated by FACS using an SH800 cell sorter from Sony
Biotechnology of the Dundee University Flow Cytometry and Cell
Sorting Facility. A 488 nm laser was used for the excitation of
fluorescence and generation of light scattering. Forward angle light
scatter (FSC) and backscatter were detected using 488 ± 17 nm
band-pass filters. Cells were distinguished from debris on the basis of
FSC-area (A) and SSC-A measurements. Single cells were
distinguished from doublets and clumps on the basis of FSC-A and
FSC-width (W) measurements. GFP fluorescence was detected using
a 525 ± 50 nm band-pass filter, and autofluorescence was detected
using a 600 ± 60 nm band-pass filter. GFP-positive cells were
identified by first assessing the background GFP and autofluorescence
of a control sample of cells which did not express GFP. Using the
measurements for GFP and autofluorescence of this sample, a
collection gate was set, which identified GFP-positive cells. The
samples to be sorted were then analyzed, and GFP-positive cells were
sorted for collection.
A single GFP +ve cell was sorted into each well of a 3 × 96 well
plate (Thermo Fisher, Waltham, MA, USA) in 200 μL of 50% filtered
preconditioned media from healthy cells and 50% fresh DMEM
containing 10% FBS and 1% (v/v) penicillin/streptomycin (pen/
strep) (#15140122, Thermo Fisher, Waltham, MA, USA) and stored
at 37 °C, 5% CO2, and 95% humidity for 2 weeks. After 2 weeks, all
visible colonies were expanded and subsequently frozen down.
4.2.4. Genomic DNA Extraction. The Brd2 expression in the post-
expanded cell lines was analyzed via western blot, and potentially
positive cell lines were subsequently harvested for genomic extraction.
Cells were plated at a density of 2 × 106 cells in the well of a 10 cm
plate. After 48 h, the cells were trypsinized using trypsin−EDTA
(0.05%) and phenol red (Thermo Fisher, Waltham, MA, USA). Once
in suspension, the trypsin−cell mixture was neutralized with FBS
(Thermo Fisher, Waltham, MA, USA). The cells were pelleted at
1500 rpm for 5 min. The remaining pellet of each clone underwent
genomic extraction following a solution-based extraction approach
using PROMEGA’s Wizard Genomic DNA Purification Kit following
the instruction provided. The DNA extracted was subsequently
analyzed using a NanoDrop spectrophotometer and stored at −20 °C
prior to use.
4.2.5. Junction PCR. Junction PCR was performed using the
following primers: forward, AGTCTGTCCACCCCCTCTAC, and
reverse, ACTCCACTCCACCGTCAAAC. The extracted genomic
DNA from the previous step was used as the template for a
subsequent PCR reaction. Using Phusion high-fidelity polymerase and
250 ng of template DNA of either clone or HEK293 wild-type
genomic DNA, a 30-cycle PCR was run with a melting temperature of
98 °C, an annealing temperature of 60 °C, and a 2 min elongation
step at 72 °C. The product of these PCRs was then subsequently run
on a 2% agarose gel containing 1× Sybersafe DNA staining reagent
(Invitrogen, Carlsbad, CA, USA) in a 1× DNA loading dye (Thermo
Fisher, Waltham, MA, USA) along with a 1× GeneRuler 1kb plus
DNA marker (Thermo Fisher, Waltham, MA, USA) at 100 V for 30
min. The run gel was imaged using a Bio-Rad Gel Doc system (Bio-
Rad, Hercules, California).
4.2.6. Genotyping. Using the agarose gel containing the junction
PCR product, appropriately sized bands from that agarose gel were
harvested using a UV imager and a scalpel. The bands chosen
corresponded to the HEK293 wild-type Brd2 junction product 1kb,
the BromoTag-Brd2 clone wild-type Brd2 junction product 1kb, and
the BromoTag-Brd2 clone Knock-in junction product 2kb. The
excised bands were subsequently removed from the agarose using a
Monarch DNA Gel Extraction Kit (NEB, Ipswich, Massachusetts).
Following extraction, the PCR product was ligated into blunt-end
vectors using a StrataClone Blunt PCR Cloning kit (Agilent, Santa
Clara, California) and subsequently transformed into Cre recombi-
nase expressing E. coli (Agilent, Santa Clara, California) and plated
onto kanamycin 50 μg/mL agar plates. A day following plating, visible
colonies were picked and grown for 16 h in 5 mL of kanamycin 50
μg/mL containing LB standard formula. The subsequent overnight
bacterial growth underwent plasmid miniprep extraction using the
Monarch Plasmid Miniprep Kit (NEB, Ipswich, Massachusetts). The
vector product recovered after extraction was subsequently analyzed
using a NanoDrop spectrophotometer. These products underwent
sequencing using an Applied Biosystems 3730 DNA analyzer using
commercially available M13-forward, M13-reverse, and eGFP-C1-
forward primers. The sequencing was performed by DNA sequencing
and services from the University of Dundee. The raw data from
sequencing was subsequently analyzed using Jalview software.
4.2.7. Dose−Response Degradation Assays. All dose−response
degradation assays were performed on the genotype-verified
heterozygous BromoTag-Brd2 HEK293 cell line. Heterozygous
BromoTag-Brd2 HEK293 cells were plated at a density of 5 × 105
cells per well of a six-well healthy plate a day before initiation of the
titration experiment. PROTAC compounds were dissolved in DMSO
at a concentration of 10 mM; from these stock concentrations,
PROTAC compounds were diluted to appropriate concentrations
using DMSO in the range of 10 μM to 1 nM. The compounds were
then added to 2 mL of DMEM (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% (v/v) FBS (Thermo Fisher, Waltham, MA,
USA) and 1% (v/v) penicillin/streptomycin (pen/strep)
(#15140122, Thermo Fisher, Waltham, MA, USA) and added to
the cells while initiating the experiment. Control compounds such as
MZ1 and cis-MZ1 were similarly dissolved in DMSO to an
appropriate concentration. All titration experiments were performed
for a total of 6 h prior to being harvested and were kept at 37 °C, 5%
CO2, and 95% humidity once treatment was applied until right before
harvesting. The cells were washed twice with PBS before being
harvested.
4.2.8. Time Course Degradation Assay. Time course degradation
assays using PROTACs AGB1 (46), AGB2 (47), and AGB3 (48)
were performed on the genotype-verified heterozygous BromoTag-
Brd2 HEK293 cell line. Heterozygous BromoTag-Brd2 HEK293 cells
were plated at a density of 5 × 105 cells per well of a six-well healthy
plate a day prior to initiating the time course assay. PROTAC’s AGB1
(46) and AGB2 (47) were diluted in DMSO to a concentration of 1
mM prior to being further diluted 1:2000 in 2 mL of DMEM to a
concentration of 500 nM per time point. PROTAC AGB3 (48) was
diluted in DMSO to a concentration of 2 mM prior to being further
diluted 1:2000 in 2 mL of DMEM to a concentration of 1 μM per
time point. The time point range was between 0 and 36 h. Treatment
was applied in a staggered fashion to enable all time points to be
harvested at the same time.
4.2.9. Recovery Assay. A recovery assay was performed using 200
nM of AGB1 (46) over a 72 h period. This was performed in the
genotype-verified heterozygous BromoTag-Brd2 HEK293 cell line.
Heterozygous BromoTag-Brd2 HEK293 cells were plated at a density
of 5 × 105 cells per well of a six-well plate a day before initiating the
recovery assay. On the experiment day, the cells were washed with
PBS before fresh DMEM containing either 200 nM of DMSO or
AGB1 (46) was applied. During treatment, the cells were kept at 37
°C, 5% CO2, and 95% humidity. After 3 h, the recovery and vehicle
control condition cells were rewashed with PBS before fresh DMEM
without 200 nM of AGB1 (46) or DMSO was applied. As for the
positive control condition, they were left with 200 nM AGB1 (46) for
the remainder of the treatment time.
4.3. Acquisition of the Polyclonal Brd4BD2 L387A Antibody.
The sheep polyclonal antibody for Brd4BD2 L387A (SA599, bleed #4
used in the assays) was generated by MRC Reagents and Services
(https://mrcppureagents.dundee.ac.uk/). To generate the polyclonal
antibody, a sheep was immunized with 0.35 mg of His-Brd4BD2 L387A
domain protein purified as previously described15,18 and prepared in a
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buffer containing 20 mM HEPES pH7.5, 0.5 M NaCl, and 1 mM
DTT. This was followed by four further injections 28 days apart.
Bleeding assessments were performed 7 days after each injection. The
antibodies were affinity-purified from serum using an antigen and
eluted with 50 mM glycine at pH 2.5, neutralized with 1 M Tris at pH
8, and dialyzed into PBS buffer using the His-Brd4BD2 L387A protein.
4.3.1. Competition Assay. Heterozygous BromoTag-Brd2
HEK293 cells were plated in six-well plates at a density of 5 × 105
cells per well in 2 mL DMEM. At the initiation of experiment, the
cells were treated with either 3 μM of MLN4924, 50 μM of MG132,
10 μM of VH298, 10 μM of ET-JQ1-OMe, or 0.1% DMSO. After 1 h,
200 nM of AGB1 (46) was added to the previously compound-
treated cells. After 3 h, the cells were harvested for subsequent
processing via western blot. Each treatment was performed in tandem
to produce two technical repeats per condition. The six-well plates
were incubated for 4 h at 37 °C and 5% CO2 throughout the
experiment.
4.3.2. Western Blotting. All cells were harvested on ice with RIPA
lysis and extraction buffer (Thermo Fisher Scientific, 89901)
supplemented with protease inhibitor cocktail (Merck,
11697498001) and Benzonase Nuclease (Sigma, E1014) before
being stored at −20 °C prior to use. Total protein quantity was
determined using the BCA protein assay (#23225, Pierce, Rockford,
Illinois). The protein concentration was determined using the BCA
assay (Thermo Fisher Scientific, 23225). The samples were then
prepared and loaded onto NuPAGE 4−12% bis−tris Midi gels
(Thermo Fisher Scientific, WG1403A), followed by the transfer of
proteins onto nitrocellulose membranes (EMD Millipore). The
membranes were blocked for 1 h prior to incubation with the
primary antibodies using 5% Milk TBST. The membranes were
probed for Brd2 (Abcam, Ab139690, 1:1000), Brd3 (Abcam,
Ab50818, 1:4000), Brd4 (Abcam, Ab128874, 1:1000), or our
polyclonal Brd4BD2 L387A antibody. Following overnight incubation
with the primary antibodies at 4 °C, the membranes were incubated
with secondary antibodies (anti-rabbit, Abcam AB216773, 1:5000 or
anti-mouse, Abcam AB216774, 1:5000) and hFABTM rhodamine
anti-tubulin antibody (Biorad, 12004165, 1:10,000) for 1 h and then
imaged with a Bio-Rad imager (LI-COR Biosciences). All western
blots were analyzed for band intensities using Image Lab from Bio-
Rad (LI-COR, Biosciences). The data extracted from these blots were
then plotted and analyzed using Prism (v. 8.2.0, GraphPad).
4.3.3. Cell Viability Assay. MV-4-11, 22RV1, and HEK293 cells
were all plated at a density of 2 × 104 cells per well of a 96-well white-
bottom plate and left to grow overnight in 50 μL of their respective
medias, namely IMDM, RPM1-1640, and DMEM(Invitrogen,
Carlsbad, CA, USA), supplemented with 10% (v/v) FBS (Thermo
Fisher, Waltham, MA, USA) and 1% (v/v) penicillin/streptomycin
(pen/strep) (#15140122, Thermo Fisher, Waltham, MA, USA) at 37
°C, 5% CO2, and 95% humidity. The cells were then treated with 50
μL of media supplemented with 2× compound treatment, including
DMSO, AGB1 (46), cis-AGB1 (52), MZ1, cis-MZ1, or staurosporine.
Cells were then left to incubate at 37 °C, 5% CO2, and 95% humidity
for 1 day (MV-4-11) or 2 days (22RV1 or HEK293) prior to
undergoing spectrophotometric analysis. All cell lines were treated
with compounds in duplicate (triplicate for DMSO controls) at a 1×
concentration in 0.1% DMSO. The compounds were serially diluted
to produce a 7-point, 10-fold titration. The cells were treated with
50:100 μL of compound for a final concentration of 10 μM:10 pM in
0.1% DMSO. At the point of spectrometric analysis, cells were treated
with 100 μL of Promega CellTiter-Glo 2.0 Cell Viability Assay
reagent. The plates were subjected to an orbital shaker for 2 min to
encourage lysis and left for a further 5 min to reach peak
luminescence. Luminescence was then recorded on a BMG Labtech
PHERAstar luminescence plate reader with recommended settings.
Data extracted from this analysis was analyzed with GraphPad Prism
(v. 8.2.0, GraphPad) and normalized to the DMSO vehicle control.
The EC50 values were derived from these plots.
4.3.4. Sample Processing, TMT Labeling, and Fractionation.
CRISPR-modified BromoTag-Brd2 HEK293 cells (5 × 106) were
seeded on a 100 cm plate 24 h before treatment. The cells were
treated with either DMSO, 1 μM AGB1, or 1 μM cis-AGB1. After 2 h
of treatment, the cells were washed twice with PBS. The cells were
lysed in 150 μL of 100 mM TEAB and 5% (w/v) sodium dodecyl
sulfate. The lysate was sonicated for 10 s and then centrifuged at
15,000g for 5 min with the supernatant collected post-centrifugation.
The samples were then quantified using a micro-BCA protein assay kit
(Thermo Fisher Scientific); 300 μg of each sample was then reduced,
alkylated, and then digested using the Strap mini protocol (protifi) as
described by the manufacturer (protifi) with some modification. The
samples were double-digested with trypsin (1:40) first overnight and
then for another 6 h with the same ratio (1:40) in 50 mM TEAB
buffer. The peptides were quantified using a quantitative fluorometric
peptide assay (Thermo Fisher Scientific). The samples (90 μg each)
were labeled with a TMT 10-plex Isobaric Label Reagent set (Thermo
Fisher Scientific) as per the manufacturer’s instructions. After labeling,
the samples were checked for labeling efficiency and then mixed,
desalted, and dried in a speed-vac at 30 °C. The samples were
redissolved in 200 μL of ammonium formate (10 mM, pH 9.5), and
peptides were fractionated using high-pH RP chromatography. A C18
column from Waters (XBridge peptide BEH, 130 Å, 3.5 μm 2.1 × 150
mm, Waters, Ireland) with a guard column (XBridge, C18, 3.5 μm,
2.1 × 10 mm, Waters) was used on an Ultimate 3000 HPLC (Thermo
Scientific). Buffers A and B used for fractionation consist, respectively,
of (A) 10 mM ammonium formate in Milli-Q water pH 9.5 and (B)
10 mM ammonium formate, pH 9.5, in 90% acetonitrile. Fractions
were collected using a WPS-3000FC auto-sampler (Thermo
Scientific) at 1 min intervals. The column and guard column were
equilibrated with 2% buffer B for 20 min at a constant flow rate of 0.2
mL/min. TMT-labeled peptides (100 μL) were injected onto the
column, and the separation gradient was started 1 min after the
sample was loaded onto the column. The peptides were eluted from
the column with a gradient of 2% buffer B to 20% buffer B in 6 min,
then from 20% buffer B to 45% buffer B in 51 min, and finally from
45% buffer B to 100% buffer B within 1 min. The column was washed
for 15 min in 100% buffer B. The fraction collection started 1 min
after injection and stopped after 80 min (total 80 fractions, 200 μL
each). To acidify the eluting peptides, 30 μL of 10% formic acid was
added to each of the 80 fractionation vials. The total number of
fractions concatenated was set to 20.
4.3.5. LC−MS Analysis. Analysis of peptides was performed on a
Q-exactive-HF (Thermo Scientific) mass spectrometer coupled with a
Dionex Ultimate 3000 RS (Thermo Scientific). The LC buffers are as
follows: buffer A [0.1% formic acid in Milli-Q water (v/v)] and buffer
B (80% acetonitrile and 0.1% formic acid in Milli-Q water (v/v)].
Aliquots of 7 μL of each sample were loaded at 10 μL/min onto a trap
column (100 μm × 2 cm, PepMap nanoViper C18 column, 5 μm, 100
Å, Thermo Scientific) equilibrated in 0.1% TFA. The trap column was
washed for 3 min at the same flow rate with 0.1% TFA and then
switched in-line with a Thermo Scientific, resolving a C18 column (75
μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). The
peptides were eluted from the column at a constant flow rate of 300
nl/min with a linear gradient from 5% buffer B (for fractions 1−10,
7% for fractions 11−20) to 35% buffer B in 125 min and then from
35% buffer B to 98% buffer B in 2 min. The column was then washed
with 98% buffer B for 20 min and re-equilibrated in 5% or 7% buffer B
for 17 min. The column was kept all the time at a constant
temperature of 50 °C. Q-exactive HF was operated in the data-
dependent positive ionization mode. The source voltage was set to
2.25 kV, and the capillary temperature was 250 °C. A scan cycle
comprised MS1 scan [m/z range from 335 to 1600, with a maximum
ion injection time of 50 ms, a resolution of 120,000, and an automatic
gain control (AGC) value of 3 × 106], followed by 15 sequentially
dependent MS2 scans (resolution 60,000) of the most intense ions
fulfilling the predefined selection criteria (AGC 1 × 105), maximum
ion injection time 200 ms, isolation window of 0.7 m/z, fixed first
mass of 100 m/z, spectrum data type: centroid, intensity threshold 5
× 104, exclusion of unassigned, singly and >6 charged precursors,
peptide match preferred, exclude isotopes on, and dynamic exclusion
time 45 s). The HCD collision energy was set to 32% of the
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normalized collision energy. The mass accuracy is checked before the
initiation of sample analysis.
4.3.6. Peptide and Protein Identification. The raw data files for all
fractions were merged and searched against the Uniprot-human-
canonical database by MaxQuant software v.1.6.0.16 for protein
identification and TMT reporter ion quantitation. The following
MaxQuant parameters were used: the enzyme used is trypsin/P; the
maximum number of missed cleavages is 2; the precursor mass
tolerance is 10 ppm; the fragment mass tolerance is 20 ppm; variable
modifications of oxidation (M), acetyl (N-term), deamidation (NQ),
and Gln → pyro-Glu (Q N-term); and fixed modifications of
carbamidomethyl (C). The data were filtered by applying a 1% false
discovery rate, followed by exclusion of proteins with fewer than two
unique peptides. The quantified proteins were filtered if the absolute
fold change difference between the three DMSO replicates was ≥1.5.
4.3.7. Protein Expression and Purification. VCB was expressed
and purified as described previously.15 Briefly, the N-terminally His6-
tagged VHL (54−213), elongin C (17−112), and elongin B (1−104)
were co-expressed in E. coli, and the complex was isolated using Ni-
affinity chromatography using TEV protease to remove His6 Tag. The
complex was further purified by anion exchange, followed by gel
filtration chromatography. Brd4-BD2L387A was expressed and purified
as described previously.15,18 Briefly, the N-terminally His6-tagged
Brd4-BD2L387A (333−460) was expressed in E. coli and isolated by Ni-
affinity chromatography using TEV protease to remove His6 Tag,
followed by gel filtration chromatography.
4.3.8. FP Binding Assay. FP competitive binding assays were
performed as described previously,17,41 with all measurements taken
using a PHERAstar FS (BMG LABTECH) with fluorescence
excitation and emission wavelengths (λ) of 485 and 520 nm,
respectively. Assays were run in triplicate using 384-well plates
(Corning 3820), with each well solution containing 15 nM VCB
protein, 10 nM 5,6-carboxyfluorescein (FAM)-labeled HIF-1α
peptide (FAM-DEALAHypYIPMDDDFQLRSF, “JC9”), and decreas-
ing concentrations of PROTACs (14-point, 2-fold serial dilution
starting from 20 μM PROTAC) or PROTACs/bromodomain (14-
point, 2-fold serial dilution starting from 20 μM PROTAC: 50 μM
bromodomain added into buffer containing 10 μM bromodomain).
All components were dissolved from stock solutions using 100 mM
bis−tris propane, 100 mM NaCl, 1 mM DTT, pH 7.0, to yield a final
assay volume of 15 μL. DMSO was added as appropriate to ensure a
final concentration of 2% v/v. Control wells containing VCB and JC9
with no compound (zero displacement), or JC9, in the absence of
protein (maximum displacement) were also included to allow for
normalization. Percentage displacement values were obtained by
normalization of controls and were plotted against log[compound].
The IC50 values were determined for each titration using nonlinear
regression analysis with Prism (v. 9.1.0, GraphPad). The Ki values
were back-calculated from the Kd for JC9 (∼1.5−2.5 nM, determined
from direct binding) and fitted IC50 values, as described
previously.41,42 Cooperativity values (α) for each PROTAC were
calculated using the ratio: α = binary Kd (−bromodomain)/ternary Kd
(+bromodomain).
4.3.9. Plasma Stability. Plasma stability studies were outsourced
and undertaken by Shanghai ChemPartner Co., Ltd. Buffer
preparation: a solution of 0.05 M sodium phosphate and 0.07 M
NaCl buffer at pH 7.4 was made by dissolving 14.505 g/L of
Na2HPO4·12H2O, 1.483 g/L of NaH2PO4·2H2O, and 4.095 g/L of
NaCl in deionized water, and the pH was adjusted with phosphoric
acid. Plasma preparation: frozen mouse plasma was thawed by placing
at 37 °C quickly. The thawed plasma was centrifuged at 3000 rpm for
8 min to remove clots, and the supernatant was pooled to be used as
the plasma in the experiment. The plasma (pH 7.4−8.0) was stored
on ice until used. AGB1 (46) and reference compound procaine were
prepared as a spiking solution (0.02 mM) compound in 0.05 mM
sodium phosphate buffer with 0.5% BSA (bovine serum albumin) and
4% v/v/DMSO. Plasma and spiking solutions were prewarmed at 37
°C for 5 min, and then 10 μL of prewarmed spiking solution B was
added into the wells designated for all the time points (5, 15, 30, 45,
and 60 min). For 0 min, 400 μL of acetonitrile-containing internal
standards (imipramine, glipizide) was added to the wells of a 0 min
plate, and then 90 μL of plasma was added. For the time points (0, 5,
15, 30, 45, and 60 min), 90 μL of prewarmed plasma was added at the
initial stage. At 5, 15, 30, 45, and 60 min, 400 μL of acetonitrile
containing the internal standard (imipramine, glipizide) was added to
the wells of the corresponding plates to stop the reaction. After
quenching, the plates were shaken at the vibrator (IKA, MTS 2/4) for
10 min (600 rpm/min) and then centrifuged at 5594g for 15 min
(Thermo Multifuge × 3R). The supernatant (50 μL) from each well
of the centrifuged plate was transferred into a new 96-well sample
plate containing 50 μL of ultra-pure water (Millipore, ZMQS50F01)
for LC/MS analysis [LC−MS/MS-49 (API6500+), UPLC-MSMS-32
(Triple Quad 6500+)]. Data was analyzed with Microsoft Excel.
4.3.10. In Vivo PK Profiling. PK profiling was outsourced and
undertaken by Shanghai ChemPartner Co., Ltd. All animal experi-
ments performed were conducted in compliance with the Institutional
Animal Care and Use Committee (IACUC) and the Office of
Laboratory Animal Welfare (OLAW) guidelines. Six- to eight-week-
old C57BL/6 male mice purchased from Jihui Laboratory Animal Co.
LTD were used in the study. AGB1 (46) was formulated in 5%
DMSO + 5% Solutol HS 15 + 90% saline at 1 mg/mL. For IV
injections, 5 mg/kg of AGB1 (46) was administered into the tail vein
of nine mice. For SC injections, 5 mg/kg of AGB1 (46) was
administered via SC injection in nine mice. The animals were
restrained manually at the designated time points (0.083, 0.25, 0.5, 1,
2, 4, and 8 h); approximately, 110 μL of blood sample was collected
via facial vein into K2EDTA tubes. Three mice per time point were
used, resulting in a total of 18 mice. The blood sample was put on ice
and centrifuged at 2000g for 5 min to obtain the plasma sample within
15 min. The plasma samples were stored at approximately −70 °C
until analysis. A 30 μL aliquot of plasma was added with 200 μL of
internal standard (diclofenac, 40 ng/mL) in 1% formic acid in MeCN.
The mixture was then vortexed for 1 min and then centrifuged for 10
min at 5800 rpm. The supernatant (100 μL) was transferred to a new
plate. The solvent (0.5 μL) was injected to LC−MS/MS. LC−MS/
MS instrument used: SCIEX LC−MS/MS-45 (Triple Quad 6500+).
Data was analyzed by WinNonLin and Microsoft Excel.
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